<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher
  PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Humana Press</PublisherName>
    <PublisherLocation>Totowa, NJ</PublisherLocation>
    <PublisherImprintName>Humana Press</PublisherImprintName>
  </PublisherInfo>
  <Series>
    <SeriesInfo SeriesType="Series" TocLevels="0">
      <SeriesID>7651</SeriesID>
      <SeriesPrintISSN>1064-3745</SeriesPrintISSN>
      <SeriesElectronicISSN>1940-6029</SeriesElectronicISSN>
      <SeriesTitle Language="En">Methods in Molecular Biology™</SeriesTitle>
      <SeriesSubTitle Language="En">Methods and Protocols</SeriesSubTitle>
      <SeriesAbbreviatedTitle>Methods Molecular Biology</SeriesAbbreviatedTitle>
    </SeriesInfo>
    <Book Language="En">
      <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterContentSeparately" OutputMedium="All" TocLevels="0">
        <BookID>978-1-60327-931-4</BookID>
        <BookTitle>Neural Cell Transplantation</BookTitle>
        <BookSubTitle>Methods and Protocols</BookSubTitle>
        <BookVolumeNumber>549</BookVolumeNumber>
        <BookSequenceNumber>549</BookSequenceNumber>
        <BookDOI>10.1007/978-1-60327-931-4</BookDOI>
        <BookTitleID>160368</BookTitleID>
        <BookPrintISBN>978-1-60327-930-7</BookPrintISBN>
        <BookElectronicISBN>978-1-60327-931-4</BookElectronicISBN>
        <BookEdition>1</BookEdition>
        <BookChapterCount>16</BookChapterCount>
        <BookCopyright>
          <CopyrightHolderName>Humana Press</CopyrightHolderName>
          <CopyrightYear>2009</CopyrightYear>
        </BookCopyright>
        <BookSubjectGroup>
          <BookSubject Code="L" Type="Primary">Life Sciences</BookSubject>
          <BookSubject Code="L16008" Priority="1" Type="Secondary">Cell Biology</BookSubject>
          <BookSubject Code="L16010" Priority="2" Type="Secondary">Stem Cells</BookSubject>
          <SubjectCollection Code="SUCO11642">Biomedical and Life Sciences</SubjectCollection>
        </BookSubjectGroup>
        <BookContext>
          <SeriesID>7651</SeriesID>
        </BookContext>
      </BookInfo>
      <BookHeader>
        <EditorGroup>
          <Editor>
            <EditorName DisplayOrder="Western">
              <GivenName>David</GivenName>
              <FamilyName>Gordon</FamilyName>
            </EditorName>
            <Contact>
              <Email>d.gordon@bristol.ac.uk</Email>
            </Contact>
          </Editor>
          <Editor>
            <EditorName DisplayOrder="Western">
              <GivenName>Neil J.</GivenName>
              <FamilyName>Scolding</FamilyName>
            </EditorName>
            <Contact>
              <Phone>+440177918-6632</Phone>
              <Email>n.j.scolding@tesco.net</Email>
            </Contact>
          </Editor>
          <Affiliation ID="AffID1">
            <OrgDivision>Frenchay Hospital</OrgDivision>
            <OrgName>University of Bristol</OrgName>
            <OrgAddress>
              <City>Bristol</City>
              <Postcode>BS16 1LE</Postcode>
              <Country>United Kingdom</Country>
            </OrgAddress>
          </Affiliation>
          <Affiliation ID="AffID2">
            <OrgDivision>Frenchay Hospital</OrgDivision>
            <OrgName>University of Bristol</OrgName>
            <OrgAddress>
              <City>Bristol</City>
              <Postcode>BS16 1LE</Postcode>
              <Country>United Kingdom</Country>
            </OrgAddress>
          </Affiliation>
        </EditorGroup>
      </BookHeader>
      <Part ID="Part2">
        <PartInfo OutputMedium="All" TocLevels="0">
          <PartID>2</PartID>
          <PartSequenceNumber>2</PartSequenceNumber>
          <PartTitle> Practical/Methodological Chapters</PartTitle>
          <PartChapterCount>13</PartChapterCount>
          <PartContext>
            <SeriesID>7651</SeriesID>
            <BookID>978-1-60327-931-4</BookID>
            <BookTitle>Neural Cell Transplantation</BookTitle>
          </PartContext>
        </PartInfo>
        <Chapter ID="Chap10" Language="En">
          <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterContentSeparately" OutputMedium="All" TocLevels="0">
            <ChapterID>10</ChapterID>
            <ChapterNumber>10</ChapterNumber>
            <ChapterDOI>10.1007/978-1-60327-931-4_10</ChapterDOI>
            <ChapterSequenceNumber>10</ChapterSequenceNumber>
            <ChapterTitle Language="En">Animal Models of Neurodegenerative Diseases</ChapterTitle>
            <ChapterFirstPage>137</ChapterFirstPage>
            <ChapterLastPage>155</ChapterLastPage>
            <ChapterCopyright>
              <CopyrightHolderName>Humana Press, a part of Springer Science+Business Media, LLC</CopyrightHolderName>
              <CopyrightYear>2009</CopyrightYear>
            </ChapterCopyright>
            <ChapterHistory>
              <RegistrationDate>
                <Year>2009</Year>
                <Month>1</Month>
                <Day>5</Day>
              </RegistrationDate>
              <OnlineDate>
                <Year>2009</Year>
                <Month>3</Month>
                <Day>23</Day>
              </OnlineDate>
            </ChapterHistory>
            <ChapterGrants Type="Regular"><MetadataGrant Grant="OpenAccess"/><AbstractGrant Grant="OpenAccess"/><BodyPDFGrant Grant="Restricted"/><BodyHTMLGrant Grant="Restricted"/><BibliographyGrant Grant="Restricted"/><ESMGrant Grant="Restricted"/></ChapterGrants><ChapterContext>
              <SeriesID>7651</SeriesID>
              <PartID>2</PartID>
              <BookID>978-1-60327-931-4</BookID>
              <BookTitle>Neural Cell Transplantation</BookTitle>
            </ChapterContext>
          </ChapterInfo>
          <ChapterHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1_10">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Wendy</GivenName>
                  <FamilyName>Phillips</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1_10">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Andrew</GivenName>
                  <FamilyName>Michell</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1_10">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Harald</GivenName>
                  <FamilyName>Pruess</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1_10" CorrespondingAffiliationID="Aff1_10">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Roger</GivenName>
                  <GivenName>A.</GivenName>
                  <FamilyName>Barker</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>wp212@cam.ac.uk</Email>
                </Contact>
              </Author>
              <Affiliation ID="Aff1_10">
                <OrgDivision>Cambridge Centre for Brain Repair</OrgDivision>
                <OrgName>University of Cambridge</OrgName>
                <OrgAddress>
                  <Street>E.D. Adrian Building, Forvie Site, 5b Bateman Street</Street>
                  <Postcode>CB2 2PY</Postcode>
                  <City>Cambridge</City>
                  <Country>UK</Country>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1_10" Language="En" OutputMedium="All">
              <Heading>Summary</Heading>
              <Para>Animal models of neurodegenerative disease are excellent tools for studying pathogenesis and therapies including cellular transplantation. In this chapter, we describe different models of Huntington’s disease and Parkinson’s disease, stereotactic surgery (used in creation of lesion models and transplantation) and finally transplantation studies in these models.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Key words:</Heading>
              <Keyword>Animal models</Keyword>
              <Keyword>Neurodegenerative disease</Keyword>
              <Keyword>Transplantation</Keyword>
              <Keyword>Neural precursor cells</Keyword>
              <Keyword>Huntington’s disease</Keyword>
              <Keyword>Parkinson’s disease</Keyword>
            </KeywordGroup>
          </ChapterHeader>
          <Body>
            <Section1 ID="Sec1_10">
              <Heading>Introduction</Heading>
              <Para>Huntington’s disease (HD) is a devastating inherited neurodegenerative condition characterised by movement disorders, cognitive deficits leading to dementia and psychiatric dysfunction. The genetic defect leads to a mutation in a ubiquitous protein, huntingtin, and neuronal loss, particularly in the caudate nucleus in early disease. The prevalence of the disease is around 1 in 10,000 (<CitationRef CitationID="CR1_10">1</CitationRef>). Onset is usually in middle age, although the range of disease onset is wide. The cell and molecular biology of the disease has been extensively studied in recent years and this has lead to potential therapies although none so far have been shown clinically to slow disease progression. The genetic abnormality in HD is an expanded triplet repeat of the bases: cysteine, adenine and guanine (CAG) (which encode glutamine, Q) on exon 1 of the “interesting transcript” (IT15) gene on chromosome 4 (<CitationRef CitationID="CR2_10">2</CitationRef>).</Para>
              <Para>Parkinson’s disease (PD) is a common neurodegenerative disease with a prevalence of 1 in 800; classically patients exhibit bradykinesia, rigidity and tremor as well as cognitive and psychiatric disturbance, but the disease is heterogeneous, affecting patients in a wide variety of ways (<CitationRef CitationID="CR3_10">3</CitationRef>). At the heart of the disease, pathologically, is degeneration of dopaminergic cells within the substantia nigra pars compacta (<CitationRef CitationID="CR4_10">4</CitationRef>), with characteristic intracytoplasmic eosinophilic inclusions called Lewy bodies. The resulting reduction in dopaminergic input to the striatum is thought to be responsible especially for the bradykinesia seen in the disease, although symptoms are only noted once about 50% of the nigral cells are lost (<CitationRef CitationID="CR4_10">4</CitationRef>).</Para>
              <Para>Animal models are invaluable in the study of early disease, of pathophysiological mechanisms (and in the case of HD, for ­example, models have been useful in elucidating the role of normal wild-type huntingtin), in interventional studies, and in therapeutic screens including cell therapy and transplantation. However, it must be realised that they still remain as models of the disease and as such only approximate to the clinical scenario of patients and these disorders.</Para>
              <Para>We will describe the different models of HD and PD, how the lesion models are created and how to choose between these different models. We will then describe what factors need to be considered when embarking upon transplantation studies, ­including those employing stem cells.</Para>
            </Section1>
            <Section1 ID="Sec2_10">
              <Heading>Materials</Heading>
              <Section2 ID="Sec3_10">
                <Heading>Striatal Excitotoxic Lesion</Heading>
                <Para>
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para>Quinolinic acid (Sigma). Dissolve first in 5 μl of 1 M NaOH and then dilute in 0.1 M phosphate buffered saline (to pH 7.4).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para>Phosphate buffered saline: 8.5 g NaCl, 0.4 g di-hydrogen sodium phosphate, 1 g di-sodium hydrogen phosphate, 1 l dH<Subscript>2</Subscript>O, pH to 7.4 with HCl.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section2>
              <Section2 ID="Sec4_10">
                <Heading>The 6-Hydroxydopamine Rodent Model</Heading>
                <Para>
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para>0.5 μl of 6-OHDA (5.5 mg free base/ml in 0.1% ascorbate, 0.9% saline) is injected over 2 min into the right medial forebrain bundle at the following stereotactic coordinates: −2.0 mm anterior to bregma, −0.7 mm lateral to bregma and −4.8 mm vertical below the dura.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para>Intraperitoneal <Emphasis Type="Italic">met</Emphasis>-amphetamine sulphate: 2.5 mg/kg dissolved in 0.9% saline. Net ipsilateral rotations (rightward rotational bias, turns/min) are recorded over 90 min.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section2>
              <Section2 ID="Sec5_10">
                <Heading>Transplantation Studies</Heading>
                <Para>
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para>Dulbecco’s modified Eagle’s media; Gibco/Life Technologies; Paisley, Scotland.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para>BrdU: Roche, Susssex, UK.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para>Rat anti-BrdU: 1 in 50 (Accurate Chemicals) or 1 in 500 (Serotec). For BrdU immunolabelling, sections should be incubated in 2 M hydrochloric acid (HCl) at 37°C for 30 min, then washed three times for 10 min in 0.1 M borate buffer (38.1 g Borax, Sigma; 1 l distilled water, pH 8.5 with NaOH) prior to block.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para>Acrylic matrix brain slicer; World Precision Instruments, Inc., Sarasota, FL, USA.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>5.</ItemNumber>
                      <ItemContent>
                        <Para>Papain (Lorne Laboratories, Twyford, UK), Dispase (Boehringer Mannheim, UK), DNase (Lorne Laboratories).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>6.</ItemNumber>
                      <ItemContent>
                        <Para>Proliferation media: Neurobasal medium (Gibco/Life Technologies) with 2% B27 (Gibco/Life Technologies), 1% PSF (Gibco/Life Technologies), 1% <Emphasis Type="SmallCaps">l</Emphasis>-glutamine, 20 ng/ml FGF-heparin (R&amp;D Systems, Oxford, UK), 20 ng/ml EGF (Sigma, Poole, UK).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>7.</ItemNumber>
                      <ItemContent>
                        <Para>Polybrene (1,5-dimethyl-1,5-diazaundecamethylene polyme­tho­bromide): Sigma-Aldrich, Germany.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>8.</ItemNumber>
                      <ItemContent>
                        <Para>X-Gal staining kit GALS-1KT, Sigma (St. Louis, MO, USA)</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec6_10">
              <Heading>Methods</Heading>
              <Section2 ID="Sec7_10">
                <Heading>Animal Models of HD</Heading>
                <Section3 ID="Sec8_10">
                  <Heading>Excitotoxic Models</Heading>
                  <Para>Given that HD is caused by a single gene defect, many robust genetic animal models have been developed. Before this defect was discovered in 1993 (<CitationRef CitationID="CR2_10">2</CitationRef>), animal models were primarily excitotoxic, targeting the site of earliest pathology in HD, namely the striatum. Intrastriatal excitotoxins in particular kainic acid, was the first to be used (<CitationRef CitationID="CR5_10">5</CitationRef>) but has now been generally superseded by quinolinic acid, which more faithfully reflects HD pathology, with loss of medium spiny gamma-amino-butyric-acid-ergic projection neurons and sparing of NADPH diaphorase neurons (<CitationRef CitationID="CR6_10">6</CitationRef>)
(<Emphasis Type="Bold">Fig.</Emphasis>
                    <InternalRef RefID="Fig1">1</InternalRef>). The mitochondrial toxin 3-nitropropionic acid given intraperitoneally produces selective striatal toxicity and a model of HD (<CitationRef CitationID="CR7_10">7</CitationRef>). As is often the case with animal models, the discovery that systemic mitochondrial inhibitors produces selective striatal toxicity not only yielded a valuable model of disease, but gave clues as to the nature of the pathophysiology of HD and fuelled the “excitotoxic theory” of HD. There is certainly some evidence for impaired energy metabolism in HD, and degeneration of mitochondria, although this may be a secondary phenomenon (<CitationRef CitationID="CR8_10">8</CitationRef>–<CitationRef CitationID="CR12_10">12</CitationRef>).<Figure Category="Standard" Float="Yes" ID="Fig1">
                      <Caption Language="En">
                        <CaptionNumber>Fig. 1.</CaptionNumber>
                        <CaptionContent>
                          <SimplePara>Photomicrograph of a sagittal section through a mouse brain showing a lesion produced by stereotactic injection of quinolinic acid into the left striatum. The striatum has been identified using acetylcholinesterase immunohistochemistry. <Emphasis Type="Italic">Asterisk</Emphasis> indicates the side of the injection; <Emphasis Type="Italic">LV</Emphasis> lateral ventricle.</SimplePara>
                        </CaptionContent>
                      </Caption>
                      <MediaObject>
                        <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-931-4_10_Fig1_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Halftone"/>
                      </MediaObject>
                    </Figure>
                  </Para>
                  <Para>The use of stereotactic apparatus allows for the injection of numerous substances including excitotoxins for lesioning and cells for transplantation. Stereotactic (Gk “movement in space”) operations use three-dimensional co-ordinates to locate a specific target in the brain. Stereotactic frames are available for small ­animals and can be used to create specific targeted lesions; in the case of HD, the striatum.
<OrderedList>
                      <ListItem>
                        <ItemNumber>1.</ItemNumber>
                        <ItemContent>
                          <Para>Fill a Hamilton syringe with the desired substance, e.g. ­quinolinic acid. Quinolinic acid (Sigma) is first dissolved in 1 M NaOH, then diluted in 0.1 M phosphate buffered saline (pH 7.4). Quinolinic acid has been used in mice in doses of 30 and 40 nmol, e.g. (<CitationRef CitationID="CR13_10">13</CitationRef>, <CitationRef CitationID="CR14_10">14</CitationRef>).</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>2.</ItemNumber>
                        <ItemContent>
                          <Para>Prepare a sterile field with sterile scissors, forceps, surgical clamps, sutures, scalpel and swabs.</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>3.</ItemNumber>
                        <ItemContent>
                          <Para>Place the animal on a heat pad, positioned underneath a ­woolen blanket. Anaesthetise the animal (<Emphasis Type="Italic">see</Emphasis>
                            <Emphasis Type="Bold">Note</Emphasis>
                            <InternalRef RefID="Sec21_10">1</InternalRef>), ­ensuring of course, the anaesthetic gas is directed to the animal and the gas scavenging system is on. The animal is often given ­antibiotic and analgesia (<Emphasis Type="Italic">see</Emphasis>
                            <Emphasis Type="Bold">Note</Emphasis>
                            <InternalRef RefID="Sec21_10">2</InternalRef>). Position the head in the frame (<Emphasis Type="Bold">Fig.</Emphasis>
                            <InternalRef RefID="Fig2">2</InternalRef>).</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>4.</ItemNumber>
                        <ItemContent>
                          <Para>Note the position of the tooth bar (most often set at zero), and insert the teeth onto the tooth bar (<Emphasis Type="Italic">see</Emphasis>
                            <Emphasis Type="Bold">Note</Emphasis>
                            <InternalRef RefID="Sec21_10">3</InternalRef>).</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>5.</ItemNumber>
                        <ItemContent>
                          <Para>The head is then kept still by securing two metal bars (different sizes of course for different animals) on either side of the head (<Emphasis Type="Italic">see</Emphasis>
                            <Emphasis Type="Bold">Note</Emphasis>
                            <InternalRef RefID="Sec21_10">4</InternalRef>), and the position of the bars should be noted using the read-off scale on the bottom of the apparatus. The head should be straight and level, and firmly positioned so as not to slip when tapped from above. A small incision (around 1 cm) can now be made in the scalp, after painting with iodide.</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>6.</ItemNumber>
                        <ItemContent>
                          <Para>Using a large microscope and lamp, bregma (the junction of the sagittal and coronal sutures) should be located (<Emphasis Type="Bold">Fig.</Emphasis>
                            <InternalRef RefID="Fig3">3</InternalRef>, <Emphasis Type="Italic">see</Emphasis>
                            <Emphasis Type="Bold">Note</Emphasis>
                            <InternalRef RefID="Sec21_10">5</InternalRef>). Bregma can then be described using co-ordinates by bringing the drill over bregma and then noting the position of the arm of the drill holder by reading off three sets of co-ordinates for its position in space (<Emphasis Type="Bold">Fig.</Emphasis>
                            <InternalRef RefID="Fig2">2</InternalRef>, <Emphasis Type="Italic">see</Emphasis>
                            <Emphasis Type="Bold">Note</Emphasis>
                            <InternalRef RefID="Sec21_10">6</InternalRef>).</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>7.</ItemNumber>
                        <ItemContent>
                          <Para>Move the scalp skin laterally to accommodate the position of the drill, otherwise hair and skin will become caught when the drill starts. Once the drill is positioned correctly, with the drill (<Emphasis Type="Italic">see</Emphasis>
                            <Emphasis Type="Bold">Note</Emphasis>
                            <InternalRef RefID="Sec21_10">7</InternalRef>) located just above the skull, it can be operated using a footpad, and lowered carefully onto the skull to create a small burr hole. Then slowly raise and remove the drill (<Emphasis Type="Italic">see</Emphasis>
                            <Emphasis Type="Bold">Note</Emphasis>
                            <InternalRef RefID="Sec21_10">8</InternalRef>).</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>8.</ItemNumber>
                        <ItemContent>
                          <Para>Replace the drill with a Hamilton syringe pre-filled with the appropriate substance. The substance, for example quinolinic acid, should be injected slowly (say 1 μl over 2–3 min), the syringe left in place for another few minutes (the same amount of time for each injection) to prevent reflux up the needle and then slowly removed (<Emphasis Type="Italic">see</Emphasis>
                            <Emphasis Type="Bold">Note</Emphasis>
                            <InternalRef RefID="Sec21_10">9</InternalRef>).</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>9.</ItemNumber>
                        <ItemContent>
                          <Para>Suture the incision, remove the animal from the frame and leave it to recover in a heated padded box with regular checks to ensure that the mouse recovers, wakes and becomes active (<Emphasis Type="Italic">see</Emphasis>
                            <Emphasis Type="Bold">Note</Emphasis>
                            <InternalRef RefID="Sec21_10">10</InternalRef>).</Para>
                        </ItemContent>
                      </ListItem>
                    </OrderedList>
                    <Figure Category="Standard" Float="Yes" ID="Fig2">
                      <Caption Language="En">
                        <CaptionNumber>Fig. 2</CaptionNumber>
                        <CaptionContent>
                          <SimplePara>Stereotactic apparatus. (<Emphasis Type="Italic">Left</Emphasis> ) The frame used to hold the animal’s head is pictured behind the woolen blanket and heat pad. The arm that holds the Hamilton syringe and drill can be seen above the frame. The anaesthetic gas and scavenging system is located at the black oval mask, above which sits the tooth bar, and the ear-bars can be seen on either side. (<Emphasis Type="Italic">Right </Emphasis>) Detail of the co-ordinate arms.</SimplePara>
                        </CaptionContent>
                      </Caption>
                      <MediaObject>
                        <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-931-4_10_Fig2_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Halftone"/>
                      </MediaObject>
                    </Figure>
                    <Figure Category="Standard" Float="Yes" ID="Fig3">
                      <Caption Language="En">
                        <CaptionNumber>Fig. 3</CaptionNumber>
                        <CaptionContent>
                          <SimplePara>Bregma is located between the sagittal and coronal sutures and is used as a neutral point for stereotactic co-ordinate readings.</SimplePara>
                        </CaptionContent>
                      </Caption>
                      <MediaObject>
                        <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-931-4_10_Fig3_HTML.jpg" Format="JPEG" Rendition="HTML" Type="LinedrawHalftone"/>
                      </MediaObject>
                    </Figure>
                  </Para>
                </Section3>
                <Section3 ID="Sec9_10">
                  <Heading>Genetic Mouse Models of HD</Heading>
                  <Para>The discovery of the genetic defect in 1993 led to the creation of genetic models of HD, with a transgenic mouse created in 1996 by Gil Bates and colleagues in London (<CitationRef CitationID="CR15_10">15</CitationRef>). Genetic ­models are arguably superior to excitotoxic models in HD, in that they reflect the disease process more faithfully, the mice can be genetically manipulated and cross-bred to tease out the molecular pathogenesis of the disease, and also because the striatum is not the only structure to dysfunction and degenerate in HD (<CitationRef CitationID="CR16_10">16</CitationRef>, <CitationRef CitationID="CR17_10">17</CitationRef>). However, they are also not without limitations.</Para>
                  <Section4 ID="Sec10_10">
                    <Heading>Transgenic Mouse Models</Heading>
                    <Para>Transgenic models are created by the random insertion of genetic material into the host genome. Thus, the host retains endogenous expression of the gene in question and the inserted genetic material is under the control of an exogenous promoter and not in the appropriate genomic context. In the case of HD, the genetic material inserted comprises either exon-1 or the full-length huntingtin gene.</Para>
                    <Para>There are now many transgenic models of HD, which ­differ in background, fragment/full-length gene, CAG repeat length, promoter, and endogenous expression of the transgene. These differences produce very diverse pathologies (in terms of ­protein aggregates and inclusions, cell loss, neuronal dysfunction) and phenotypes. In general, few repeats, low expression and full-length transgenes produce a model with a less severe disease course. Conversely, many repeats, high expression and N-terminal ­fragments of the gene produce models with severe disease and a short lifespan. Despite this, there is very little striatal cell loss in these models, which may limit their usefulness (<CitationRef CitationID="CR15_10">15</CitationRef>). It has been argued that these latter models reflect juvenile HD, given the large number of repeats and severe phenotype (<CitationRef CitationID="CR1_10">1</CitationRef>, <CitationRef CitationID="CR18_10">18</CitationRef>). Genetic background also influences mouse phenotype, with for example, different rates of neurogenesis (<CitationRef CitationID="CR19_10">19</CitationRef>) and response to ­excitotoxins (<CitationRef CitationID="CR20_10">20</CitationRef>) dependent on strain. Even for the same model, such as the R6/2 model (<CitationRef CitationID="CR15_10">15</CitationRef>), breeding procedures and husbandry are different in different laboratories, which may significantly affect the life expectancy and behaviour of the mice (<CitationRef CitationID="CR21_10">21</CitationRef>). Due to genetic anticipation, whereby trinucleotide repeats expand in length as they are inherited possibly due to gametic instability (<CitationRef CitationID="CR22_10">22</CitationRef>), the CAG repeat length expands with every generation. If this is not checked and mice are not re-derived (i.e. not using males from late generations with very expanded repeat lengths) then CAG repeat lengths can reach large proportions, into the 200s. In humans, the htt gene normally has less than 36 CAG repeats and the mutant gene has greater than 39 CAG repeats (<CitationRef CitationID="CR1_10">1</CitationRef>, <CitationRef CitationID="CR23_10">23</CitationRef>, <CitationRef CitationID="CR24_10">24</CitationRef>). Having said this, however, it may be litter origin and environmental sources of variability (such as age at weaning, environmental enrichment, provision of mash to prevent dehydration, number of cage mates, etc.) that matter more to phenotype (<CitationRef CitationID="CR21_10">21</CitationRef>). For example, the Morton colony of R6/2 mice is environmentally enriched, with running wheels and toys as well as regular provision of wet mash, and the mice from this colony tend to have greater longevity and less severe disease than mice from non-enriched colonies (<CitationRef CitationID="CR25_10">25</CitationRef>). These differences may affect some experimental results given that environmental enrichment can affect neurogenesis, for example (<CitationRef CitationID="CR26_10">26</CitationRef>).</Para>
                  </Section4>
                  <Section4 ID="Sec11_10">
                    <Heading>Knock-In Models</Heading>
                    <Para>Knock-in models are created by the insertion of CAG repeats or CAG repeats with a part of the gene (from an exogenous source; these are known as chimeric knock-ins) directly into the relevant host gene. Thus, the inserted genetic material will be under the endogenous promoter and in the appropriate genomic context. Initially it was thought that these models were poor because they displayed little pathological and phenotypical changes but this view has been revised with more knowledge about these mice and it may be that they in fact are the best model of adult onset HD precisely because the disease onset is slow (<CitationRef CitationID="CR27_10">27</CitationRef>). The chimeric knock-in mice may be better models because they carry a sequence that encodes for a polyproline tract, which may be involved in huntingtin protein structure and some protein–protein interactions (<CitationRef CitationID="CR27_10">27</CitationRef>).</Para>
                  </Section4>
                </Section3>
                <Section3 ID="Sec12_10">
                  <Heading>Non-Mouse Models of HD</Heading>
                  <Para>Cellular models of HD allow high throughput screening of therapeutically promising compounds, as well as allowing detailed study of molecular mechanisms of pathogenesis mediated by the mutant gene. Cellular models comprise, for example, cells cultured from HD patients, such as fibroblasts (<CitationRef CitationID="CR28_10">28</CitationRef>) or cells transfected with the mutant gene (<CitationRef CitationID="CR29_10">29</CitationRef>).</Para>
                  <Para>Neuronal intranuclear inclusions and neurodegeneration have been described in a <Emphasis Type="Italic">Drosophila melanogaster</Emphasis> model of HD (<CitationRef CitationID="CR30_10">30</CitationRef>), and also a <Emphasis Type="Italic">Caenorhabditis elegans</Emphasis> model (<CitationRef CitationID="CR31_10">31</CitationRef>). These models are important as an intermediate step from cellular to mammalian models, because of their simplicity and availability of a complete genome sequence. They are often used for suppressor screens, which aim to identify genes that modify the disease process.</Para>
                  <Para>Zebrafish (<Emphasis Type="Italic">Dania rerio</Emphasis>) are attractive model organisms by virtue of their rapid developmental time and transparency of their embryos, and have been used successfully in mutagenesis screens. The zebrafish HD gene homologue has been recently characterised and a zebrafish HD model developed (<CitationRef CitationID="CR32_10">32</CitationRef>, <CitationRef CitationID="CR33_10">33</CitationRef>).</Para>
                  <Para>The choice of model for a particular experiment should depend on the pathology (cell loss, abnormal protein aggregation and inclusions), neuronal dysfunction and transcriptional changes, and the motor and behavioural phenotype displayed by the mouse. Mice with a short lifespan allow rapid completion of experiments but have less value in exploring specifically the gradual disease process. Mice that have been extensively studied, such as the R6/2 model, are useful experimentally. Finally, logistical matters such as commercial and inter-laboratory availability must also be considered.</Para>
                  <Para>To answer a specific scientific question, however, it is best that many models are studied. For example, some HD models (the fragment models) are resistant to excitotoxins (<CitationRef CitationID="CR13_10">13</CitationRef>, <CitationRef CitationID="CR14_10">14</CitationRef>, <CitationRef CitationID="CR34_10">34</CitationRef>, <CitationRef CitationID="CR35_10">35</CitationRef>), some display no change from wild-type animals (<CitationRef CitationID="CR36_10">36</CitationRef>) and others show enhanced sensitivity (<CitationRef CitationID="CR37_10">37</CitationRef>).</Para>
                  <Para>There is an extensive literature on mouse models of HD but details on specific models are beyond the scope of this chapter. There are some excellent and comprehensive review articles on this subject (<CitationRef CitationID="CR38_10">38</CitationRef>, <CitationRef CitationID="CR39_10">39</CitationRef>) and specifically on the R6/2 model (<CitationRef CitationID="CR40_10">40</CitationRef>), use of models in elucidating pathophysiology (<CitationRef CitationID="CR41_10">41</CitationRef>) and therapeutics, (<CitationRef CitationID="CR40_10">40</CitationRef>) and knock-in models (<CitationRef CitationID="CR27_10">27</CitationRef>).</Para>
                </Section3>
              </Section2>
              <Section2 ID="Sec13_10">
                <Heading>Animal Models of PD</Heading>
                <Para>There are a large number of animal models of PD, from transgenic <Emphasis Type="Italic">Drosophila</Emphasis>, which are particularly useful for genetic research, to <Emphasis Type="Italic">C. elegans</Emphasis> models and up to primate models of disease (<CitationRef CitationID="CR42_10">42</CitationRef>, <CitationRef CitationID="CR43_10">43</CitationRef>). Perhaps the most widely used are rodent models – on the one hand transgenic models (which we shall illustrate by using the example of α-synuclein transgenic mice) and on the other hand toxic models (we shall give the example of 6-hydroxydopamine (6-OHDA) lesioned rats since they are often used to assess the efficacy of intracerebral transplants). There exist other interesting models, such as those that use adenoviral vectors to drive targeted overexpression of α-synuclein in adult animals (<CitationRef CitationID="CR44_10">44</CitationRef>). Detailed descriptions of these are beyond the scope of this chapter.</Para>
                <Section3 ID="Sec14_10">
                  <Heading>The 6-Hydroxydopamine Rodent Model</Heading>
                  <Para>Although there are several toxin-induced models of PD, the 6-OHDA model (<Emphasis Type="Bold">Fig.</Emphasis>
                    <InternalRef RefID="Fig4">4</InternalRef>) will be explained here since it can be used to quantify the response to striatal transplants of dopamine-rich tissue. 6-OHDA is structurally extremely similar to dopamine (with an extra hydroxyl group on the carbon ring) and is actively taken up by dopaminergic and noradrenergic transporters on dopaminergic cells, thus explaining its relative selectivity for this cell type. Within the neuron it is metabolised to create free radicals, including hydrogen peroxide and reactive quinines, which damage molecules, resulting in cell death.<Figure Category="Standard" Float="Yes" ID="Fig4">
                      <Caption Language="En">
                        <CaptionNumber>Fig. 4</CaptionNumber>
                        <CaptionContent>
                          <SimplePara>The 6-OHDA model of Parkinson’s disease. Right-sided injection of the medial forebrain bundle causes degeneration of the nigrostriatal tract on that side. Amphetamine induces dopamine release from the unlesioned dopaminergic striatal nerve terminals, increasing rotational bias towards the side with the lesion. Transplantation of dopaminergic cells to the right striatum can ameliorate the rotational asymmetry if &gt;200 dopaminergic cells survive. Apomorphine rotation relies on using low dose apomorphine to stimulate supersensitive dopamine receptors in the dopamine-denervated striatum. In this case, the animal rotates away from the side of the lesion.</SimplePara>
                        </CaptionContent>
                      </Caption>
                      <MediaObject>
                        <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-931-4_10_Fig4_HTML.jpg" Format="JPEG" Rendition="HTML" Type="LinedrawHalftone"/>
                      </MediaObject>
                    </Figure>
                  </Para>
                  <Para>Since 6-OHDA does not cross the blood–brain barrier it must be injected directly into the brain to exert its effects. Injection into the medial forebrain bundle, that carries ascending dopaminergic and serotonergic fibres to the striatum, results in irreversible dopaminergic cell death in the substantia nigra and ventral tegmentum. Unlike Parkinson’s disease, there are no Lewy bodies formed, but like in the human disease there does seem to be relative sensitivity of dopaminergic neurons in the substantia nigra pars compacta. Bilateral lesions result in severe aphagia, adipsia and akinesia (<CitationRef CitationID="CR45_10">45</CitationRef>), whereas unilateral lesions result in a far less sick animal with contralateral deficits in grip strength, sensory neglect and a postural bias towards the lesioned side (<CitationRef CitationID="CR46_10">46</CitationRef>). Rodents receiving unilateral injections of this toxin develop a spontaneous head-to-tail turning motion in the direction of the lesion, a behaviour exacerbated by stimulation of the dopaminergic system, such as use of an ice-cold surface, or pharmacologically with amphetamine or apomorphine.</Para>
                  <Para>Importantly, the lesions induced by 6-OHDA injection of the medial forebrain bundle cause cell death within 24 h, and are stable and complete within a couple of weeks (<CitationRef CitationID="CR46_10">46</CitationRef>). This is in contrast to the lesions induced by intrastriatal injection of the toxin that produces a progressive retrograde loss of dopaminergic neurons that can last for months (<CitationRef CitationID="CR47_10">47</CitationRef>), and is helpful if chronic slow degenerative lesions are required.</Para>
                  <Para>The assessment of unilateral medial forebrain bundle 6-OHDA lesions (and their subsequent repair) is most commonly performed after intraperitoneal injection of amphetamine, and measured using automated rotometer bowls (<CitationRef CitationID="CR48_10">48</CitationRef>). Amphetamine acts for 3–4 h, causing catecholamine release, especially dopamine, from pre-synaptic nerve terminals on the intact side, thus increasing the tendency for mice to rotate towards the side of the lesion (<Emphasis Type="Bold">Fig.</Emphasis>
                    <InternalRef RefID="Fig4">4</InternalRef>). This technique provides a rotation score that is stable, and, most importantly, one that can be quantified. The rate of turning correlates with striatal dopamine depletion (<CitationRef CitationID="CR46_10">46</CitationRef>), and the effects of grafting can be examined animal by animal (<CitationRef CitationID="CR49_10">49</CitationRef>). Furthermore, the technique benefits from being extremely well studied and relatively well understood. There are potential pitfalls with the interpretation of results from this technique. First, an improved rotation score, in other words a reduction in rotational bias, does not only arise from a restoration of dopaminergic tone on the lesioned side since a further lesion on the intact side would have a similar effect. Furthermore, it has even been shown that a large striatal lesion ipsilateral to the original 6-OHDA lesion can result in improved rotational behaviour, especially after apomorphine, which relies on its action on the supersensitive dopamine receptors in the striatum on the side of the median forebrain ­bundle lesion (<CitationRef CitationID="CR50_10">50</CitationRef>). Thus to better understand the benefit of any new treatment (such as transplantation), a range of behavioural tests should be considered, such as paw reaching, stepping and measurement of sensory neglect in addition to rotational behaviour (<CitationRef CitationID="CR51_10">51</CitationRef>).</Para>
                </Section3>
                <Section3 ID="Sec15_10">
                  <Heading>α-Synuclein Transgenic Mice</Heading>
                  <Para>The first transgenic mouse overexpressing wild-type human α-synuclein was reported in 2000 (<CitationRef CitationID="CR52_10">52</CitationRef>). Expression of α-synuclein was driven by the platelet-derived growth factor-β promoter, resulting in prominent nuclear and cytoplasmic α-synuclein-positive granular inclusions in several regions of the brain including the substantia nigra, but no fibrillar pathology characteristic of Lewy bodies. The mice lost dopaminergic nerve terminals, and the ­striatal tyrosine hydroxylase (TH) levels and activity were reduced in line with the highest expression of the transgene. In time, a reduction in rotarod locomotor ability was detectable.</Para>
                  <Para>Since this original publication, numerous other α-synuclein transgenic mouse lines have been studied. Of course each is ­different to the other, but a few general points can be made. First, it is interesting to note that models using the TH promoter to target α-synuclein expression to the nigra fail to cause dopaminergic cell loss, suggesting that the relationship between α-synuclein accumulation and dopaminergic cell death is not straightforward. Second, some of the mouse lines that overexpress the A53T mutant, but not A30P, tend to develop a striking motor ­neuron degeneration in the spinal cord, accompanied by the denervation of neuromuscular synapses (<CitationRef CitationID="CR53_10">53</CitationRef>–<CitationRef CitationID="CR55_10">55</CitationRef>). Third, although not all publications report such findings, there does seem to be an association between the finding of truncated α-synuclein and filamentous neuropathology in some transgenic mouse models (<CitationRef CitationID="CR54_10">54</CitationRef>, <CitationRef CitationID="CR55_10">55</CitationRef>).</Para>
                  <Para>There are many possible explanations for the differences in pathology and phenotype between these different transgenic mouse models. Of course, both the type of α-synuclein used and the promoter driving its expression are likely to affect the outcome – one suggestion has been that the transgene needs to be expressed in a variety of cell types, including glia, to have maximal effect (<CitationRef CitationID="CR56_10">56</CitationRef>). The level of expression achieved in the models varies from about 0.5 to 30 times the normal amount of endogenous mouse α-synuclein, suggesting some models may fail to achieve a critical threshold. For example, expression levels in the nigra tend to be very low, whereas in some models there is high expression in the motor neurons of the spinal cord, explaining the sensitivity of these cells described above. Of course more practical details such as the background strain of mouse used and type of behavioural test used will affect the results and their comparability between different models.</Para>
                  <Para>Considering these transgenic mouse lines together, there are a number of reasons why mouse dopaminergic neurons might be relatively immune to the overexpression of mutant α-synuclein. Seven amino acids differ between human and mouse endogenous α-synuclein, including the encoding of threonine in place of alanine at position 53, perhaps explaining why A53T mutants are handled differently. Moreover, these subtle differences may affect the tertiary structure of α-synuclein, and therefore its interaction with the human species and aggregation. Alternatively, mouse neurons may activate cell survival pathways not available in other species, such as those that have been proposed to explain the minimal amyloid plaque formation in transgenic mouse models of Alzheimer’s disease expressing mutant human amyloid ­precursor protein (<CitationRef CitationID="CR57_10">57</CitationRef>).</Para>
                  <Para>Although many models demonstrated some dysfunction of the dopaminergic system (be it subtle alterations in neuronal morphology or decreased striatal dopamine concentrations), the lack of dopaminergic cell death is disappointing. It is possible that this may relate to the observation that the interaction of human α-synuclein with the endogenous mouse species results in slower fibrillization (<CitationRef CitationID="CR58_10">58</CitationRef>), suggesting that an α-synuclein null background might create a more severe model (if the fibrils are the toxic species) – perhaps more akin to the profound model in Drosophila, that have no natural endogenous α-synuclein (<CitationRef CitationID="CR42_10">42</CitationRef>).</Para>
                </Section3>
              </Section2>
              <Section2 ID="Sec16_10">
                <Heading>Transplantation in HD and PD Models</Heading>
                <Para>Transplantation studies in HD and PD models have served to research and optimise this technique as a prelude to human studies of foetal transplantation, which are designed to repair primary pathology through cell replacement. These studies have also served other purposes, for example, xenotransplants as an alternative to foetal allo-transplantation have revealed the processes underlying rejection and immunology, and neural precursor cell (NPC) transplants also as an alternative to foetal allo-transplantation and have been used to study the behaviour of stem cells when grafted into different microenvironments.</Para>
                <Para>When attempting transplantation studies, several factors must be considered, such as donor tissue, host site and microenvironment, the transplantation procedure itself, post-graft “training” (<CitationRef CitationID="CR59_10">59</CitationRef>) and behavioural testing (<Emphasis Type="Bold">Fig.</Emphasis>
                  <InternalRef RefID="Fig5">5</InternalRef>).<Figure Category="Standard" Float="Yes" ID="Fig5">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 5</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Schema illustrating a standard protocol for assessment of transplanted tissue in a disease model.</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject>
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-931-4_10_Fig5_HTML.jpg" Format="JPEG" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                </Para>
                <Section3 ID="Sec17_10">
                  <Heading>Donor Tissue</Heading>
                  <Para>In terms of donor tissue, the nature and number of cells to be transplanted are critical factors, along with their age of harvest and storage. In addition, the modes of engrafting including the media in which the cells are stored and to be transplanted are important factors. Dulbecco’s modified Eagle’s media has been found to be superior to Hank’s balanced salt solution in the preparation of embryonic striatal tissue for example (<CitationRef CitationID="CR60_10">60</CitationRef>). Furthermore, NPCs may survive better when grafted as neurospheres, rather than as a cell suspension (<CitationRef CitationID="CR61_10">61</CitationRef>). Cells should be kept on ice and used as soon as possible. The number of cells transplanted is important (<CitationRef CitationID="CR62_10">62</CitationRef>), and cells from embryos proliferate and survive better than cells from adult tissue (<CitationRef CitationID="CR63_10">63</CitationRef>).</Para>
                </Section3>
                <Section3 ID="Sec18_10">
                  <Heading>Labelling of Cells for Transplantation</Heading>
                  <Para>When transplanting cells from one species into the brain of a recipient from the same species, the donor cells must be labelled in order to distinguish donor cells from host cells. If ­transplanting R6/2 cells into a wild-type brain for example, then the donor cells can be easily identified using antibodies against mutant ­huntingtin (<CitationRef CitationID="CR64_10">64</CitationRef>). Cells from a male donor can be distinguished from a female host by virtue of a Y chromosome assay (<CitationRef CitationID="CR65_10">65</CitationRef>). Donor tissue may come from an animal expressing a fluorescent protein, but often the host and the donor should come from the same genetic background, which may not always be possible. Specifically using NPCs as donor tissue, these can be labelled using either bromodeoxyuridine (BrdU) or viral transfection.</Para>
                  <Para>BrdU is a thymidine analogue and intercalates into DNA ­during the S-phase of mitosis thus labelling proliferating cells (<CitationRef CitationID="CR66_10">66</CitationRef>). Proliferating NPCs in culture can be labelled with pulses of BrdU and a dose of 10 μM is generally accepted to be non-toxic to dividing cells. Caldwell and colleagues, however, have shown that this concentration of BrdU is selectively toxic to ­developing neurons, something that does not happen at a dose of 0.2 μM (<CitationRef CitationID="CR67_10">67</CitationRef>). NPCs are often labelled 24 h before transplantation. At least the time of the S-phase should be given prior to transplantation; in the case of a mouse this is 6.5 h (<CitationRef CitationID="CR68_10">68</CitationRef>), but adult dentate gyrus neurospheres are smaller and take more time to develop than subventricular zone neurospheres (<CitationRef CitationID="CR69_10">69</CitationRef>) and so it may be necessary to pulse for, say 3 days prior to transplantation (personal observations). It is wise to take an aliquot of cells prior to transplantation and confirm the labelling of cells in vitro using immunohistochemistry. The use of BrdU to label proliferating cells has been cautioned by a recent study showing that in adult (and developing) brains, host cells can take up BrdU from transplanted dead cells pre-labelled with 10 μM BrdU (<CitationRef CitationID="CR70_10">70</CitationRef>).</Para>
                  <Para>Genetic modification of NPCs to express green fluorescent protein (GFP) is commonly done ex vivo using viral vectors. Several vectors are available for the gene delivery, each with their own advantages. The vast spectrum of retro-, adeno- and ­lentiviral vectors for gene-transfer is reviewed elsewhere (<CitationRef CitationID="CR71_10">71</CitationRef>).</Para>
                  <Para>Lentiviral vectors are widespread due to their high transduction efficiency, and protocols for generation of a GFP-expressing lentiviral vectors are well established (<CitationRef CitationID="CR72_10">72</CitationRef>). For example, ­deletions in the flanking long-terminal repeat sequence of the human immunodeficiency virus (HIV)-1-derived lentiviral vector cause self-inactivation of the vector but still allow integration. The GFP gene is subcloned into the construct and driven by the cytomegalovirus (CMV) promotor.</Para>
                  <Para>Retroviruses require integration into the host genome in order for gene expression to occur, and some retroviruses lack nuclear transport machinery and can enter the cell only when the nuclear membrane breaks down during cell division (<CitationRef CitationID="CR73_10">73</CitationRef>). Retrovirus-mediated gene-transfer with a retroviral construct can include incorporation of an internal ribosomal entry site (IRES) as well as lacZ gene encoding <Emphasis Type="Italic">E. coli</Emphasis> β-galactosidase for later lacZ screening or XGal histochemistry (<CitationRef CitationID="CR74_10">74</CitationRef>). In either case, the ­vector is then used for cotransfection of cells together with a helper plasmid encoding required lenti- or retroviral genes. The cells eventually become viral producer cells and release high titers of replication-incompetent virus into the medium. For infection of NPCs, virus aliquots are thawed on ice and applied onto dividing NPCs in the presence of polybrene. Medium is replenished after 4 h. After 3 days cells are washed, trypsinised, counted, diluted and used for transplantation. With multiple passages the number of GFP- or XGal-positive cells gradually decreases, thus cells should be studied during the first 4 weeks in culture.</Para>
                  <Para>Using viral gene-transfer further enables NPCs to produce a certain protein that might promote cell differentiation or survival after transplantation. Thus, viral transfection of NPCs can be a useful tool beyond cell tracking.</Para>
                </Section3>
                <Section3 ID="Sec19_10">
                  <Heading>Host Site</Heading>
                  <Para>The age of the host must be considered, and younger animals are able to better integrate grafts (<CitationRef CitationID="CR75_10">75</CitationRef>). It may be the case that grafts integrate better into a lesioned, as opposed to intact, area (<CitationRef CitationID="CR76_10">76</CitationRef>). Further, it is possible that transplanted cells survive better in the tissue surrounding a lesion rather than the lesion core. In the case of PD, tissue is grafted into the striatum rather than the substantia nigra, as it is difficult to produce new long distance dopaminergic projection neurons from the substantia nigra to the striatum.</Para>
                </Section3>
                <Section3 ID="Sec20_10">
                  <Heading>Transplantation Procedure</Heading>
                  <Para>Transplantation is performed using stereotactic apparatus. When using neurospheres for transplantation, they should either be small enough to fit into the needle bore without becoming stuck or they should be chopped prior to transplantation (<CitationRef CitationID="CR77_10">77</CitationRef>). Chopping of neurospheres is very simple: intact spheres are picked up using a Pasteur pipette and placed into a petri dish ­containing a small volume of media. The neurospheres are then simply chopped into small pieces using a sterile razor blade. To ensure chopped neurospheres are actually taken up into the needle of the Hamilton syringe, this can be directly visualised under a microscope just prior to transplantation. It is often a good idea to use a needle with internal plunger to ensure material does not become stuck within the needle bore. Post-procedure, we usually allow at least 7 days for graft integration.</Para>
                </Section3>
              </Section2>
            </Section1>
            <Section1 ID="Sec21_10">
              <Heading>Notes</Heading>
              <Para>
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para>In our laboratory, for mice, surgery is often performed under halothane anaesthesia, induced in a chamber with inflow of 3-litres/minute (l/min) halothane (Fluothane, Merial) and
1.5-l/min oxygen. Maintenance anaesthesia is achieved with 2.5-l/min halothane, 0.6-l/min oxygen and 0.8-l/min nitrous oxide through a nose mask.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para>A subcutaneous injection of analgesic (Rimadyl, 5 mg/kg; Pfizer, Kent, UK is used in our laboratory) and antibiotic (Terramycin, 60 mg/kg; Pfizer) dissolved in 0.9% sterile saline may be given prior to the onset of surgery.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para>This can be fiddly and it helps to open the jaw slightly and slide the open mouth from the side of the tooth bar then position it in the centre of the bar.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para>The bars should be secured firmly to just avoid the head slipping, but not too tightly. It often helps to slide a finger under the animal’s jaw to keep the head level while placing the bars. In our laboratory, for mice, we use bars with grips at the end, which is secured on either side of the head, although some laboratories use “ear-bars”, where a tapered end is inserted into the animals’ ears.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para>When the skull is moist, bregma can be seen more easily, and it often helps to tap gently on the skull, which dips it down slightly thus visually enhancing the juxtaposition of the sutures.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para>The location of the target structure will have been determined previously, using a brain atlas, previous literature and/or a previous experiment using, say, India ink to inject and locate a structure. For example, for the mouse striatum, the following co-ordinates have been used: 0.7 mm rostral to bregma, 1.9 mm lateral to the midline and 2.5 mm ventral to the dura (<CitationRef CitationID="CR13_10">13</CitationRef>, <CitationRef CitationID="CR14_10">14</CitationRef>). Thus, 0.7 mm should be added (if the desired position was caudal to bregma then of course the ­relevant amount should be subtracted) to the antero-posterior bregma reading and 1.9 mm should be added to the lateral bregma reading and the drill positioned accordingly (<Emphasis Type="Bold">Fig.</Emphasis>
                        <InternalRef RefID="Fig2">2</InternalRef>).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para>For mice, a Foredom dental drill with a bit of 0.5-mm dia-meter is often used.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>8.</ItemNumber>
                    <ItemContent>
                      <Para>It is helpful to make a mark on the drill arm demonstrating which way to turn the knob to ensure the drill is raised and not erroneously lowered, which might inadvertently damage the cortex.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>9.</ItemNumber>
                    <ItemContent>
                      <Para>Again, it is helpful to have a mark on the drill arm to ensure the syringe is raised and not erroneously inserted more deeply.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>10.</ItemNumber>
                    <ItemContent>
                      <Para>This is remarkably quick; around 5–10 min for mice.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section1>
          </Body>
          <BodyRef FileRef="BodyRef/PDF/978-1-60327-931-4_Chapter_10.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
          <ChapterBackmatter>
            <Acknowledgments>
              <Heading>Acknowledgments</Heading>
              <SimplePara>The authors would like to thank Mrs. Pam Tyers for excellent technical advice and assistance and Dr. Jenny Morton for provision of transgenic HD mice. The corresponding author’s work was supported by the Medical Research Council.</SimplePara>
            </Acknowledgments>
            <Bibliography ID="Bib1_10">
              <Heading>References</Heading>
              <Citation ID="CR1_10">
                <CitationNumber>1.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>G.</Initials>
                    <FamilyName>Bates</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Harper</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L.</Initials>
                    <FamilyName>Jones</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <BookTitle>Huntington’s Disease. 3rd edition</BookTitle>
                  <PublisherName>Oxford University Press</PublisherName>
                  <PublisherLocation>Oxford</PublisherLocation>
                </BibBook>
                <BibUnstructured>Bates, G., Harper, P., and Jones, L. (2002) Huntington’s Disease. 3rd edition, Oxford University Press, Oxford.</BibUnstructured>
              </Citation>
              <Citation ID="CR2_10">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <InstitutionalAuthorName>The Huntington’s Disease Collaborative Research Group</InstitutionalAuthorName>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes</ArticleTitle>
                  <JournalTitle>The Huntington’s Disease Collaborative Research Group Cell</JournalTitle>
                  <VolumeID>72</VolumeID>
                  <FirstPage>971</FirstPage>
                  <LastPage>983</LastPage>
                </BibArticle>
                <BibUnstructured>The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes The Huntington’s Disease Collaborative Research Group <Emphasis Type="Italic">Cell</Emphasis> 72, 971–983.</BibUnstructured>
              </Citation>
              <Citation ID="CR3_10">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T.</Initials>
                    <FamilyName>Foltynie</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Brayne</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.A.</Initials>
                    <FamilyName>Barker</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">The heterogeneity of idiopathic Parkinson’s disease</ArticleTitle>
                  <JournalTitle>J. Neurol.</JournalTitle>
                  <VolumeID>249</VolumeID>
                  <FirstPage>138</FirstPage>
                  <LastPage>145</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11985378</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/PL00007856</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Foltynie, T., Brayne, C., and Barker, R.A. (2002) The heterogeneity of idiopathic Parkinson’s disease J. Neurol. 249, 138–145.</BibUnstructured>
              </Citation>
              <Citation ID="CR4_10">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J.M.</Initials>
                    <FamilyName>Fearnley</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.J.</Initials>
                    <FamilyName>Lees</FamilyName>
                  </BibAuthorName>
                  <Year>1991</Year>
                  <ArticleTitle Language="En">Ageing and Parkinson’s disease: substantia nigra regional selectivity</ArticleTitle>
                  <JournalTitle>Brain</JournalTitle>
                  <VolumeID>114</VolumeID>
                  <FirstPage>2283</FirstPage>
                  <LastPage>2301</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1933245</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1093/brain/114.5.2283</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Fearnley, J.M. and Lees, A.J. (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity Brain 114, 2283–2301.</BibUnstructured>
              </Citation>
              <Citation ID="CR5_10">
                <CitationNumber>5.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J.T.</Initials>
                    <FamilyName>Coyle</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.</Initials>
                    <FamilyName>Schwarcz</FamilyName>
                  </BibAuthorName>
                  <Year>1976</Year>
                  <ArticleTitle Language="En">Lesion of striatal neurones with kainic acid provides a model for Huntington’s chorea</ArticleTitle>
                  <JournalTitle>Nature</JournalTitle>
                  <VolumeID>263</VolumeID>
                  <FirstPage>244</FirstPage>
                  <LastPage>246</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8731</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/263244a0</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaE1cXmvFCrsg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Coyle, J.T. and Schwarcz, R. (1976) Lesion of striatal neurones with kainic acid provides a model for Huntington’s chorea Nature 263, 244–246.</BibUnstructured>
              </Citation>
              <Citation ID="CR6_10">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.F.</Initials>
                    <FamilyName>Beal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.J.</Initials>
                    <FamilyName>Ferrante</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K.J.</Initials>
                    <FamilyName>Swartz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N.W.</Initials>
                    <FamilyName>Kowall</FamilyName>
                  </BibAuthorName>
                  <Year>1991</Year>
                  <ArticleTitle Language="En">Chronic quinolinic acid lesions in rats closely resemble Huntington’s disease</ArticleTitle>
                  <JournalTitle>J. Neurosci.</JournalTitle>
                  <VolumeID>11</VolumeID>
                  <FirstPage>1649</FirstPage>
                  <LastPage>1659</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1710657</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3MXlsFKgtLo%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Beal, M.F., Ferrante, R.J., Swartz, K.J., and Kowall, N.W. (1991) Chronic quinolinic acid lesions in rats closely resemble Huntington’s disease J. Neurosci. 11, 1649–1659.</BibUnstructured>
              </Citation>
              <Citation ID="CR7_10">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Brouillet</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Jacquard</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N.</Initials>
                    <FamilyName>Bizat</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D.</Initials>
                    <FamilyName>Blum</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington’s disease</ArticleTitle>
                  <JournalTitle>J. Neurochem.</JournalTitle>
                  <VolumeID>95</VolumeID>
                  <FirstPage>1521</FirstPage>
                  <LastPage>1540</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16300642</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1471-4159.2005.03515.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XhsVKjtQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Brouillet, E., Jacquard, C., Bizat, N., and Blum, D. (2005) 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington’s disease J. Neurochem. 95, 1521–1540.</BibUnstructured>
              </Citation>
              <Citation ID="CR8_10">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H.H.</Initials>
                    <FamilyName>Goebel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.</Initials>
                    <FamilyName>Heipertz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W.</Initials>
                    <FamilyName>Scholz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K.</Initials>
                    <FamilyName>Iqbal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I.</Initials>
                    <FamilyName>Tellez-Nagel</FamilyName>
                  </BibAuthorName>
                  <Year>1978</Year>
                  <ArticleTitle Language="En">Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies</ArticleTitle>
                  <JournalTitle>Neurology</JournalTitle>
                  <VolumeID>28</VolumeID>
                  <FirstPage>23</FirstPage>
                  <LastPage>31</LastPage>
                  <Occurrence Type="PID">
                    <Handle>145549</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1212/WNL.28.1.23</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaE1cXhtVaqt7Y%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Goebel, H.H., Heipertz, R., Scholz, W., Iqbal, K., and Tellez-Nagel, I. (1978) Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies Neurology 28, 23–31.</BibUnstructured>
              </Citation>
              <Citation ID="CR9_10">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>B.G.</Initials>
                    <FamilyName>Jenkins</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W.J.</Initials>
                    <FamilyName>Koroshetz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.F.</Initials>
                    <FamilyName>Beal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B.R.</Initials>
                    <FamilyName>Rosen</FamilyName>
                  </BibAuthorName>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">Evidence for impairment of energy metabolism in vivo in Huntington’s disease using localized 1H NMR spectroscopy</ArticleTitle>
                  <JournalTitle>Neurology</JournalTitle>
                  <VolumeID>43</VolumeID>
                  <FirstPage>2689</FirstPage>
                  <LastPage>2695</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8255479</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1212/WNL.43.12.2689</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK2c%2FnslCjsw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Jenkins, B.G., Koroshetz, W.J., Beal, M.F., and Rosen, B.R. (1993) Evidence for impairment of energy metabolism in vivo in Huntington’s disease using localized 1H NMR spectroscopy Neurology 43, 2689–2695.</BibUnstructured>
              </Citation>
              <Citation ID="CR10_10">
                <CitationNumber>10.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S.J.</Initials>
                    <FamilyName>Tabrizi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Workman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.E.</Initials>
                    <FamilyName>Hart</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L.</Initials>
                    <FamilyName>Mangiarini</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Mahal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G.</Initials>
                    <FamilyName>Bates</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse</ArticleTitle>
                  <JournalTitle>Ann. Neurol.</JournalTitle>
                  <VolumeID>47</VolumeID>
                  <FirstPage>80</FirstPage>
                  <LastPage>86</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10632104</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/1531-8249(200001)47:1&lt;80::AID-ANA13&gt;3.0.CO;2-K</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3c%2FpsF2ltw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Tabrizi, S.J., Workman, J., Hart, P.E., Mangiarini, L., Mahal, A., Bates, G., et al (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse Ann. Neurol. 47, 80–86.</BibUnstructured>
              </Citation>
              <Citation ID="CR11_10">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Guidetti</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V.</Initials>
                    <FamilyName>Charles</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E.Y.</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.H.</Initials>
                    <FamilyName>Reddy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.H.</Initials>
                    <FamilyName>Kordower</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W.O.</Initials>
                    <FamilyName>Whetsell</FamilyName>
                    <Suffix>Jr</Suffix>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production</ArticleTitle>
                  <JournalTitle>Exp. Neurol.</JournalTitle>
                  <VolumeID>169</VolumeID>
                  <FirstPage>340</FirstPage>
                  <LastPage>350</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11358447</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1006/exnr.2000.7626</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXjsF2lt70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Guidetti, P., Charles, V., Chen, E.Y., Reddy, P.H., Kordower, J.H., Whetsell, W.O., Jr., et al (2001) Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production Exp. Neurol. 169, 340–350.</BibUnstructured>
              </Citation>
              <Citation ID="CR12_10">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>W.A.</Initials>
                    <FamilyName>Brennan</FamilyName>
                    <Suffix>Jr</Suffix>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E.D.</Initials>
                    <FamilyName>Bird</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.R.</Initials>
                    <FamilyName>Aprille</FamilyName>
                  </BibAuthorName>
                  <Year>1985</Year>
                  <ArticleTitle Language="En">Regional mitochondrial respiratory activity in Huntington’s disease brain</ArticleTitle>
                  <JournalTitle>J. Neurochem.</JournalTitle>
                  <VolumeID>44</VolumeID>
                  <FirstPage>1948</FirstPage>
                  <LastPage>1950</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2985766</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1471-4159.1985.tb07192.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL2MXks12htb4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Brennan, W.A., Jr., Bird, E.D., and Aprille, J.R. (1985) Regional mitochondrial respiratory activity in Huntington’s disease brain J. Neurochem. 44, 1948–1950.</BibUnstructured>
              </Citation>
              <Citation ID="CR13_10">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>O.</Initials>
                    <FamilyName>Hansson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Petersen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Leist</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Nicotera</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.F.</Initials>
                    <FamilyName>Castilho</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Brundin</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Transgenic mice expressing a Huntington’s disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity</ArticleTitle>
                  <JournalTitle>Proc. Natl Acad. Sci. USA</JournalTitle>
                  <VolumeID>96</VolumeID>
                  <FirstPage>8727</FirstPage>
                  <LastPage>8732</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10411943</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.96.15.8727</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXkslOktbo%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hansson, O., Petersen, A., Leist, M., Nicotera, P., Castilho, R.F., and Brundin, P. (1999) Transgenic mice expressing a Huntington’s disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity Proc. Natl Acad. Sci. USA 96, 8727–8732.</BibUnstructured>
              </Citation>
              <Citation ID="CR14_10">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>W.</Initials>
                    <FamilyName>Phillips</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.J.</Initials>
                    <FamilyName>Morton</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.A.</Initials>
                    <FamilyName>Barker</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Abnormalities of neurogenesis in the R6/2 mouse model of Huntington’s disease are attributable to the in vivo microenvironment</ArticleTitle>
                  <JournalTitle>J. Neurosci.</JournalTitle>
                  <VolumeID>25</VolumeID>
                  <FirstPage>11564</FirstPage>
                  <LastPage>11576</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16354914</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1523/JNEUROSCI.3796-05.2005</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XhsVektA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Phillips, W., Morton, A.J., and Barker, R.A. (2005) Abnormalities of neurogenesis in the R6/2 mouse model of Huntington’s disease are attributable to the in vivo microenvironment J. Neurosci. 25, 11564–11576.</BibUnstructured>
              </Citation>
              <Citation ID="CR15_10">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L.</Initials>
                    <FamilyName>Mangiarini</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K.</Initials>
                    <FamilyName>Sathasivam</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Seller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B.</Initials>
                    <FamilyName>Cozens</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Harper</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Hetherington</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice</ArticleTitle>
                  <JournalTitle>Cell</JournalTitle>
                  <VolumeID>87</VolumeID>
                  <FirstPage>493</FirstPage>
                  <LastPage>506</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8898202</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0092-8674(00)81369-0</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28XmvVOrtL0%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C. et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice Cell 87, 493–506.</BibUnstructured>
              </Citation>
              <Citation ID="CR16_10">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N.</Initials>
                    <FamilyName>Pavese</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T.C.</Initials>
                    <FamilyName>Andrews</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D.J.</Initials>
                    <FamilyName>Brooks</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.K.</Initials>
                    <FamilyName>Ho</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.E.</Initials>
                    <FamilyName>Rosser</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.A.</Initials>
                    <FamilyName>Barker</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Progressive striatal and cortical dopamine receptor dysfunction in Huntington’s disease: a PET study</ArticleTitle>
                  <JournalTitle>Brain</JournalTitle>
                  <VolumeID>126</VolumeID>
                  <FirstPage>1127</FirstPage>
                  <LastPage>1135</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12690052</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1093/brain/awg119</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Pavese, N., Andrews, T.C., Brooks, D.J., Ho, A.K., Rosser, A.E., Barker, R.A., et al (2003) Progressive striatal and cortical dopamine receptor dysfunction in Huntington’s disease: a PET study Brain 126, 1127–1135.</BibUnstructured>
              </Citation>
              <Citation ID="CR17_10">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H.D.</Initials>
                    <FamilyName>Rosas</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W.J.</Initials>
                    <FamilyName>Koroshetz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y.I.</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Skeuse</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Vangel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.E.</Initials>
                    <FamilyName>Cudkowicz</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis</ArticleTitle>
                  <JournalTitle>Neurology</JournalTitle>
                  <VolumeID>60</VolumeID>
                  <FirstPage>1615</FirstPage>
                  <LastPage>1620</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12771251</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1212/01.WNL.0000065888.88988.6E</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3s3kvVWqtA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rosas, H.D., Koroshetz, W.J., Chen, Y.I., Skeuse, C., Vangel, M., Cudkowicz, M.E., et al (2003) Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis Neurology 60, 1615–1620.</BibUnstructured>
              </Citation>
              <Citation ID="CR18_10">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H.</Initials>
                    <FamilyName>Telenius</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H.P.</Initials>
                    <FamilyName>Kremer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Theilmann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.E.</Initials>
                    <FamilyName>Andrew</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Almqvist</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Anvret</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent</ArticleTitle>
                  <JournalTitle>Hum. Mol. Genet.</JournalTitle>
                  <VolumeID>2</VolumeID>
                  <FirstPage>1535</FirstPage>
                  <LastPage>1540</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8268906</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1093/hmg/2.10.1535</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2cXivVKmsg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Telenius, H., Kremer, H.P., Theilmann, J., Andrew, S.E., Almqvist, E., Anvret, M., et al (1993) Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent Hum. Mol. Genet. 2, 1535–1540.</BibUnstructured>
              </Citation>
              <Citation ID="CR19_10">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G.</Initials>
                    <FamilyName>Kempermann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H.G.</Initials>
                    <FamilyName>Kuhn</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F.H.</Initials>
                    <FamilyName>Gage</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Genetic influence on neurogenesis in the dentate gyrus of adult mice</ArticleTitle>
                  <JournalTitle>Proc. Natl Acad. Sci. USA</JournalTitle>
                  <VolumeID>94</VolumeID>
                  <FirstPage>10409</FirstPage>
                  <LastPage>10414</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9294224</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.94.19.10409</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXmt1Gjtrs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kempermann, G., Kuhn, H.G., and Gage, F.H. (1997) Genetic influence on neurogenesis in the dentate gyrus of adult mice Proc. Natl Acad. Sci. USA 94, 10409–10414.</BibUnstructured>
              </Citation>
              <Citation ID="CR20_10">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C.W.</Initials>
                    <FamilyName>Shuttleworth</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.A.</Initials>
                    <FamilyName>Connor</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Strain-dependent differences in calcium signaling predict excitotoxicity in murine hippocampal neurons</ArticleTitle>
                  <JournalTitle>J. Neurosci.</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <FirstPage>4225</FirstPage>
                  <LastPage>4236</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11404408</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXktlKls7s%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Shuttleworth, C.W. and Connor, J.A. (2001) Strain-dependent differences in calcium signaling predict excitotoxicity in murine hippocampal neurons J. Neurosci. 21, 4225–4236.</BibUnstructured>
              </Citation>
              <Citation ID="CR21_10">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Hockly</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.M.</Initials>
                    <FamilyName>Cordery</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B.</Initials>
                    <FamilyName>Woodman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Mahal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D.A.</Initials>
                    <FamilyName>Van</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Blakemore</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Environmental enrichment slows disease progression in R6/2 Huntington’s disease mice</ArticleTitle>
                  <JournalTitle>Ann. Neurol.</JournalTitle>
                  <VolumeID>51</VolumeID>
                  <FirstPage>235</FirstPage>
                  <LastPage>242</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11835380</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/ana.10094</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hockly, E., Cordery, P.M., Woodman, B., Mahal, A., Van, D.A., Blakemore, C., et al (2002) Environmental enrichment slows disease progression in R6/2 Huntington’s disease mice Ann. Neurol. 51, 235–242.</BibUnstructured>
              </Citation>
              <Citation ID="CR22_10">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.E.</Initials>
                    <FamilyName>MacDonald</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G.</Initials>
                    <FamilyName>Barnes</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Srinidhi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.P.</Initials>
                    <FamilyName>Duyao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.M.</Initials>
                    <FamilyName>Ambrose</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.H.</Initials>
                    <FamilyName>Myers</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">Gametic but not somatic instability of CAG repeat length in Huntington’s disease</ArticleTitle>
                  <JournalTitle>J. Med. Genet.</JournalTitle>
                  <VolumeID>30</VolumeID>
                  <FirstPage>982</FirstPage>
                  <LastPage>986</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8133508</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1136/jmg.30.12.982</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2cXisVWktbo%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>MacDonald, M.E., Barnes, G., Srinidhi, J., Duyao, M.P., Ambrose, C.M., Myers, R.H., et al (1993) Gametic but not somatic instability of CAG repeat length in Huntington’s disease J. Med. Genet. 30, 982–986.</BibUnstructured>
              </Citation>
              <Citation ID="CR23_10">
                <CitationNumber>23.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D.C.</Initials>
                    <FamilyName>Rubinsztein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Leggo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.</Initials>
                    <FamilyName>Coles</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Almqvist</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V.</Initials>
                    <FamilyName>Biancalana</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.J.</Initials>
                    <FamilyName>Cassiman</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Phenotypic characterization of individuals with 30–40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36–39 repeats</ArticleTitle>
                  <JournalTitle>Am. J. Hum. Genet.</JournalTitle>
                  <VolumeID>59</VolumeID>
                  <FirstPage>16</FirstPage>
                  <LastPage>22</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8659522</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28XksFSisLg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rubinsztein, D.C., Leggo, J., Coles, R., Almqvist, E., Biancalana, V., Cassiman, J.J., et al (1996) Phenotypic characterization of individuals with 30–40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36–39 repeats Am. J. Hum. Genet. 59, 16–22.</BibUnstructured>
              </Citation>
              <Citation ID="CR24_10">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R.G.</Initials>
                    <FamilyName>Snell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.C.</Initials>
                    <FamilyName>MacMillan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.P.</Initials>
                    <FamilyName>Cheadle</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I.</Initials>
                    <FamilyName>Fenton</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L.P.</Initials>
                    <FamilyName>Lazarou</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Davies</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington’s disease</ArticleTitle>
                  <JournalTitle>Nat. Genet.</JournalTitle>
                  <VolumeID>4</VolumeID>
                  <FirstPage>393</FirstPage>
                  <LastPage>397</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8401588</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/ng0893-393</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3sXltlKrs70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Snell, R.G., MacMillan, J.C., Cheadle, J.P., Fenton, I., Lazarou, L.P., Davies, P., et al (1993) Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington’s disease Nat. Genet. 4, 393–397.</BibUnstructured>
              </Citation>
              <Citation ID="CR25_10">
                <CitationNumber>25.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R.J.</Initials>
                    <FamilyName>Carter</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.J.</Initials>
                    <FamilyName>Hunt</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.J.</Initials>
                    <FamilyName>Morton</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington’s disease gene</ArticleTitle>
                  <JournalTitle>Mov. Disord.</JournalTitle>
                  <VolumeID>15</VolumeID>
                  <FirstPage>925</FirstPage>
                  <LastPage>937</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11009201</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/1531-8257(200009)15:5&lt;925::AID-MDS1025&gt;3.0.CO;2-Z</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3cvlt1yhsg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Carter, R.J., Hunt, M.J., and Morton, A.J. (2000) Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington’s disease gene Mov. Disord. 15, 925–937.</BibUnstructured>
              </Citation>
              <Citation ID="CR26_10">
                <CitationNumber>26.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G.</Initials>
                    <FamilyName>Kempermann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H.G.</Initials>
                    <FamilyName>Kuhn</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F.H.</Initials>
                    <FamilyName>Gage</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">More hippocampal neurons in adult mice living in an enriched environment</ArticleTitle>
                  <JournalTitle>Nature</JournalTitle>
                  <VolumeID>386</VolumeID>
                  <FirstPage>493</FirstPage>
                  <LastPage>495</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9087407</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/386493a0</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXisVWjs70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kempermann, G., Kuhn, H.G., and Gage, F.H. (1997) More hippocampal neurons in adult mice living in an enriched environment Nature 386, 493–495.</BibUnstructured>
              </Citation>
              <Citation ID="CR27_10">
                <CitationNumber>27.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L.B.</Initials>
                    <FamilyName>Menalled</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Knock-in mouse models of Huntington’s disease</ArticleTitle>
                  <JournalTitle>NeuroRx</JournalTitle>
                  <VolumeID>2</VolumeID>
                  <FirstPage>465</FirstPage>
                  <LastPage>470</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16389309</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1602/neurorx.2.3.465</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Menalled, L.B. (2005) Knock-in mouse models of Huntington’s disease NeuroRx 2, 465–470.</BibUnstructured>
              </Citation>
              <Citation ID="CR28_10">
                <CitationNumber>28.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Hamel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I.E.</Initials>
                    <FamilyName>Goetz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Roberts</FamilyName>
                  </BibAuthorName>
                  <Year>1981</Year>
                  <ArticleTitle Language="En">Glutamic acid decarboxylase and gamma-aminobutyric acid in Huntington’s disease fibroblasts and other cultured cells, determined by a [3H]muscimol radioreceptor assay</ArticleTitle>
                  <JournalTitle>J. Neurochem.</JournalTitle>
                  <VolumeID>37</VolumeID>
                  <FirstPage>1032</FirstPage>
                  <LastPage>1038</LastPage>
                  <Occurrence Type="PID">
                    <Handle>6275031</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1471-4159.1981.tb04491.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL3MXmtFymsr4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hamel, E., Goetz, I.E., and Roberts, E. (1981) Glutamic acid decarboxylase and gamma-aminobutyric acid in Huntington’s disease fibroblasts and other cultured cells, determined by a [3H]muscimol radioreceptor assay J. Neurochem. 37, 1032–1038.</BibUnstructured>
              </Citation>
              <Citation ID="CR29_10">
                <CitationNumber>29.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>F.</Initials>
                    <FamilyName>Saudou</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Finkbeiner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D.</Initials>
                    <FamilyName>Devys</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.E.</Initials>
                    <FamilyName>Greenberg</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions</ArticleTitle>
                  <JournalTitle>Cell</JournalTitle>
                  <VolumeID>95</VolumeID>
                  <FirstPage>55</FirstPage>
                  <LastPage>66</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9778247</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0092-8674(00)81782-1</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXmslWlsrs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M.E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions Cell 95, 55–66.</BibUnstructured>
              </Citation>
              <Citation ID="CR30_10">
                <CitationNumber>30.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G.R.</Initials>
                    <FamilyName>Jackson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I.</Initials>
                    <FamilyName>Salecker</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X.</Initials>
                    <FamilyName>Dong</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X.</Initials>
                    <FamilyName>Yao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N.</Initials>
                    <FamilyName>Arnheim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.W.</Initials>
                    <FamilyName>Faber</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons</ArticleTitle>
                  <JournalTitle>Neuron</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <FirstPage>633</FirstPage>
                  <LastPage>642</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9768849</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0896-6273(00)80573-5</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXms1eht7c%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Jackson, G.R., Salecker, I., Dong, X., Yao, X., Arnheim, N., Faber, P.W., et al (1998) Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons Neuron 21, 633–642.</BibUnstructured>
              </Citation>
              <Citation ID="CR31_10">
                <CitationNumber>31.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P.W.</Initials>
                    <FamilyName>Faber</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.R.</Initials>
                    <FamilyName>Alter</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.E.</Initials>
                    <FamilyName>MacDonald</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.C.</Initials>
                    <FamilyName>Hart</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron</ArticleTitle>
                  <JournalTitle>Proc. Natl Acad. Sci. USA</JournalTitle>
                  <VolumeID>96</VolumeID>
                  <FirstPage>179</FirstPage>
                  <LastPage>184</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9874792</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.96.1.179</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXjvV2hsg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Faber, P.W., Alter, J.R., MacDonald, M.E., and Hart, A.C. (1999) Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron Proc. Natl Acad. Sci. USA 96, 179–184.</BibUnstructured>
              </Citation>
              <Citation ID="CR32_10">
                <CitationNumber>32.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C.A.</Initials>
                    <FamilyName>Karlovich</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.M.</Initials>
                    <FamilyName>John</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L.</Initials>
                    <FamilyName>Ramirez</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D.Y.</Initials>
                    <FamilyName>Stainier</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.M.</Initials>
                    <FamilyName>Myers</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Characterization of the Huntington’s disease (HD) gene homologue in the zebrafish Danio rerio</ArticleTitle>
                  <JournalTitle>Gene</JournalTitle>
                  <VolumeID>217</VolumeID>
                  <FirstPage>117</FirstPage>
                  <LastPage>125</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9795179</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0378-1119(98)00342-4</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXmsVOis70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Karlovich, C.A., John, R.M., Ramirez, L., Stainier, D.Y., and Myers, R.M. (1998) Characterization of the Huntington’s disease (HD) gene homologue in the zebrafish Danio rerio Gene 217, 117–125.</BibUnstructured>
              </Citation>
              <Citation ID="CR33_10">
                <CitationNumber>33.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>V.M.</Initials>
                    <FamilyName>Miller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.F.</Initials>
                    <FamilyName>Nelson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.M.</Initials>
                    <FamilyName>Gouvion</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Williams</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Rodriguez-Lebron</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.Q.</Initials>
                    <FamilyName>Harper</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo</ArticleTitle>
                  <JournalTitle>J. Neurosci.</JournalTitle>
                  <VolumeID>25</VolumeID>
                  <FirstPage>9152</FirstPage>
                  <LastPage>9161</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16207874</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1523/JNEUROSCI.3001-05.2005</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXhtFGktr3E</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Miller, V.M., Nelson, R.F., Gouvion, C.M., Williams, A., Rodriguez-Lebron, E., Harper, S.Q., et al (2005) CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo J. Neurosci. 25, 9152–9161.</BibUnstructured>
              </Citation>
              <Citation ID="CR34_10">
                <CitationNumber>34.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A.J.</Initials>
                    <FamilyName>Morton</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W.</Initials>
                    <FamilyName>Leavens</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Mice transgenic for the human Huntington’s disease mutation have reduced sensitivity to kainic acid toxicity</ArticleTitle>
                  <JournalTitle>Brain Res. Bull.</JournalTitle>
                  <VolumeID>52</VolumeID>
                  <FirstPage>51</FirstPage>
                  <LastPage>59</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10779703</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0361-9230(00)00238-0</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXisFGqtr8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Morton, A.J. and Leavens, W. (2000) Mice transgenic for the human Huntington’s disease mutation have reduced sensitivity to kainic acid toxicity Brain Res. Bull. 52, 51–59.</BibUnstructured>
              </Citation>
              <Citation ID="CR35_10">
                <CitationNumber>35.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.A.</Initials>
                    <FamilyName>Hickey</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.J.</Initials>
                    <FamilyName>Morton</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Mice transgenic for the Huntington’s disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity</ArticleTitle>
                  <JournalTitle>J. Neurochem.</JournalTitle>
                  <VolumeID>75</VolumeID>
                  <FirstPage>2163</FirstPage>
                  <LastPage>2171</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11032906</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1046/j.1471-4159.2000.0752163.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXns1eisr4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hickey, M.A. and Morton, A.J. (2000) Mice transgenic for the Huntington’s disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity J. Neurochem. 75, 2163–2171.</BibUnstructured>
              </Citation>
              <Citation ID="CR36_10">
                <CitationNumber>36.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Petersen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K.</Initials>
                    <FamilyName>Chase</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Z.</Initials>
                    <FamilyName>Puschban</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>DiFiglia</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Brundin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N.</Initials>
                    <FamilyName>Aronin</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington’s disease</ArticleTitle>
                  <JournalTitle>Exp. Neurol.</JournalTitle>
                  <VolumeID>175</VolumeID>
                  <FirstPage>297</FirstPage>
                  <LastPage>300</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12009780</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1006/exnr.2002.7885</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XjsFOhurg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Petersen, A., Chase, K., Puschban, Z., DiFiglia, M., Brundin, P., and Aronin, N. (2002) Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington’s disease Exp. Neurol. 175, 297–300.</BibUnstructured>
              </Citation>
              <Citation ID="CR37_10">
                <CitationNumber>37.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.M.</Initials>
                    <FamilyName>Zeron</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>O.</Initials>
                    <FamilyName>Hansson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N.</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.L.</Initials>
                    <FamilyName>Wellington</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B.R.</Initials>
                    <FamilyName>Leavitt</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Brundin</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease</ArticleTitle>
                  <JournalTitle>Neuron</JournalTitle>
                  <VolumeID>33</VolumeID>
                  <FirstPage>849</FirstPage>
                  <LastPage>860</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11906693</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0896-6273(02)00615-3</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38Xis1Wrsbk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zeron, M.M., Hansson, O., Chen, N., Wellington, C.L., Leavitt, B.R., Brundin, P. et al (2002) Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease Neuron 33, 849–860.</BibUnstructured>
              </Citation>
              <Citation ID="CR38_10">
                <CitationNumber>38.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L.B.</Initials>
                    <FamilyName>Menalled</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.F.</Initials>
                    <FamilyName>Chesselet</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Mouse models of Huntington’s disease</ArticleTitle>
                  <JournalTitle>Trends Pharmacol. Sci.</JournalTitle>
                  <VolumeID>23</VolumeID>
                  <FirstPage>32</FirstPage>
                  <LastPage>39</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11804649</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0165-6147(00)01884-8</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38Xms1emsg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Menalled, L.B. and Chesselet, M.F. (2002) Mouse models of Huntington’s disease Trends Pharmacol. Sci. 23, 32–39.</BibUnstructured>
              </Citation>
              <Citation ID="CR39_10">
                <CitationNumber>39.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G.P.</Initials>
                    <FamilyName>Bates</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L.</Initials>
                    <FamilyName>Mangiarini</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Mahal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.W.</Initials>
                    <FamilyName>Davies</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Transgenic models of Huntington’s disease</ArticleTitle>
                  <JournalTitle>Hum. Mol. Genet.</JournalTitle>
                  <VolumeID>6</VolumeID>
                  <FirstPage>1633</FirstPage>
                  <LastPage>1637</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9300654</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1093/hmg/6.10.1633</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXlvVyntrw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bates, G.P., Mangiarini, L., Mahal, A., and Davies, S.W. (1997) Transgenic models of Huntington’s disease Hum. Mol. Genet. 6, 1633–1637.</BibUnstructured>
              </Citation>
              <Citation ID="CR40_10">
                <CitationNumber>40.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J.Y.</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N.</Initials>
                    <FamilyName>Popovic</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Brundin</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies</ArticleTitle>
                  <JournalTitle>NeuroRx</JournalTitle>
                  <VolumeID>2</VolumeID>
                  <FirstPage>447</FirstPage>
                  <LastPage>464</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16389308</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1602/neurorx.2.3.447</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Li, J.Y., Popovic, N., and Brundin, P. (2005) The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies NeuroRx 2, 447–464.</BibUnstructured>
              </Citation>
              <Citation ID="CR41_10">
                <CitationNumber>41.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D.C.</Initials>
                    <FamilyName>Rubinsztein</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Lessons from animal models of Huntington’s disease</ArticleTitle>
                  <JournalTitle>Trends Genet.</JournalTitle>
                  <VolumeID>18</VolumeID>
                  <FirstPage>202</FirstPage>
                  <LastPage>209</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11932021</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0168-9525(01)02625-7</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XisV2htbs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rubinsztein, D.C. (2002) Lessons from animal models of Huntington’s disease Trends Genet. 18, 202–209.</BibUnstructured>
              </Citation>
              <Citation ID="CR42_10">
                <CitationNumber>42.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.B.</Initials>
                    <FamilyName>Feany</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W.W.</Initials>
                    <FamilyName>Bender</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">A Drosophila model of Parkinson’s disease</ArticleTitle>
                  <JournalTitle>Nature</JournalTitle>
                  <VolumeID>404</VolumeID>
                  <FirstPage>394</FirstPage>
                  <LastPage>398</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10746727</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/35006074</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXitlyltLc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Feany, M.B. and Bender, W.W. (2000) A Drosophila model of Parkinson’s disease Nature 404, 394–398.</BibUnstructured>
              </Citation>
              <Citation ID="CR43_10">
                <CitationNumber>43.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Lakso</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Vartiainen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.M.</Initials>
                    <FamilyName>Moilanen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Sirvio</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.H.</Initials>
                    <FamilyName>Thomas</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.</Initials>
                    <FamilyName>Nass</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein</ArticleTitle>
                  <JournalTitle>J. Neurochem.</JournalTitle>
                  <VolumeID>86</VolumeID>
                  <FirstPage>165</FirstPage>
                  <LastPage>172</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12807436</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1046/j.1471-4159.2003.01809.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXltFelurc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lakso, M., Vartiainen, S., Moilanen, A.M., Sirvio, J., Thomas, J.H., Nass, R. et al (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein J. Neurochem. 86, 165–172.</BibUnstructured>
              </Citation>
              <Citation ID="CR44_10">
                <CitationNumber>44.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D.</Initials>
                    <FamilyName>Kirik</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Bjorklund</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors</ArticleTitle>
                  <JournalTitle>Trends Neurosci.</JournalTitle>
                  <VolumeID>26</VolumeID>
                  <FirstPage>386</FirstPage>
                  <LastPage>392</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12850435</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0166-2236(03)00164-4</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXlt1eiu74%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kirik, D. and Bjorklund, A. (2003) Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors Trends Neurosci. 26, 386–392.</BibUnstructured>
              </Citation>
              <Citation ID="CR45_10">
                <CitationNumber>45.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.J.</Initials>
                    <FamilyName>Zigmond</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E.M.</Initials>
                    <FamilyName>Stricker</FamilyName>
                  </BibAuthorName>
                  <Year>1972</Year>
                  <ArticleTitle Language="En">Deficits in feeding behavior after intraventricular injection of 6-hydroxydopamine in rats</ArticleTitle>
                  <JournalTitle>Science.</JournalTitle>
                  <VolumeID>177</VolumeID>
                  <FirstPage>1211</FirstPage>
                  <LastPage>1214</LastPage>
                  <Occurrence Type="PID">
                    <Handle>5057630</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1126/science.177.4055.1211</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaE3sXivVw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zigmond, M.J. and Stricker, E.M. (1972) Deficits in feeding behavior after intraventricular injection of 6-hydroxydopamine in rats Science. 177, 1211–1214.</BibUnstructured>
              </Citation>
              <Citation ID="CR46_10">
                <CitationNumber>46.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R.A.</Initials>
                    <FamilyName>Barker</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.B.</Initials>
                    <FamilyName>Dunnett</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Functional integration of neural grafts in Parkinson’s disease</ArticleTitle>
                  <JournalTitle>Nat. Neurosci.</JournalTitle>
                  <VolumeID>2</VolumeID>
                  <FirstPage>1047</FirstPage>
                  <LastPage>1048</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10570477</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/15969</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXnslKqt78%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Barker, R.A. and Dunnett, S.B. (1999) Functional integration of neural grafts in Parkinson’s disease Nat. Neurosci. 2, 1047–1048.</BibUnstructured>
              </Citation>
              <Citation ID="CR47_10">
                <CitationNumber>47.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H.</Initials>
                    <FamilyName>Sauer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W.H.</Initials>
                    <FamilyName>Oertel</FamilyName>
                  </BibAuthorName>
                  <Year>1994</Year>
                  <ArticleTitle Language="En">Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat</ArticleTitle>
                  <JournalTitle>Neuroscience</JournalTitle>
                  <VolumeID>59</VolumeID>
                  <FirstPage>401</FirstPage>
                  <LastPage>415</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7516500</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0306-4522(94)90605-X</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2cXisVWktL4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sauer, H. and Oertel, W.H. (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat Neuroscience 59, 401–415.</BibUnstructured>
              </Citation>
              <Citation ID="CR48_10">
                <CitationNumber>48.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>U.</Initials>
                    <FamilyName>Ungerstedt</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G.W.</Initials>
                    <FamilyName>Arbuthnott</FamilyName>
                  </BibAuthorName>
                  <Year>1970</Year>
                  <ArticleTitle Language="En">Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system</ArticleTitle>
                  <JournalTitle>Brain Res.</JournalTitle>
                  <VolumeID>24</VolumeID>
                  <FirstPage>485</FirstPage>
                  <LastPage>493</LastPage>
                  <Occurrence Type="PID">
                    <Handle>5494536</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0006-8993(70)90187-3</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaE3M%2Fotl2msA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ungerstedt, U. and Arbuthnott, G.W. (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system Brain Res. 24, 485–493.</BibUnstructured>
              </Citation>
              <Citation ID="CR49_10">
                <CitationNumber>49.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S.B.</Initials>
                    <FamilyName>Dunnett</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T.D.</Initials>
                    <FamilyName>Hernandez</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Summerfield</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G.H.</Initials>
                    <FamilyName>Jones</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G.</Initials>
                    <FamilyName>Arbuthnott</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Graft-derived recovery from 6-OHDA lesions: specificity of ventral mesencephalic graft tissues</ArticleTitle>
                  <JournalTitle>Exp. Brain Res.</JournalTitle>
                  <VolumeID>71</VolumeID>
                  <FirstPage>411</FirstPage>
                  <LastPage>424</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2901978</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/BF00247501</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaL1M%2FgsFCqsA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Dunnett, S.B., Hernandez, T.D., Summerfield, A., Jones, G.H., and Arbuthnott, G. (1988) Graft-derived recovery from 6-OHDA lesions: specificity of ventral mesencephalic graft tissues Exp. Brain Res. 71, 411–424.</BibUnstructured>
              </Citation>
              <Citation ID="CR50_10">
                <CitationNumber>50.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R.</Initials>
                    <FamilyName>Barker</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.B.</Initials>
                    <FamilyName>Dunnett</FamilyName>
                  </BibAuthorName>
                  <Year>1994</Year>
                  <ArticleTitle Language="En">Ibotenic acid lesions of the striatum reduce drug-induced rotation in the 6-hydroxydopamine-lesioned rat</ArticleTitle>
                  <JournalTitle>Exp. Brain Res.</JournalTitle>
                  <VolumeID>101</VolumeID>
                  <FirstPage>365</FirstPage>
                  <LastPage>374</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7851507</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/BF00227330</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXjs12gsLs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Barker, R. and Dunnett, S.B. (1994) Ibotenic acid lesions of the striatum reduce drug-induced rotation in the 6-hydroxydopamine-lesioned rat Exp. Brain Res. 101, 365–374.</BibUnstructured>
              </Citation>
              <Citation ID="CR51_10">
                <CitationNumber>51.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R.</Initials>
                    <FamilyName>Iancu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Mohapel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.</Initials>
                    <FamilyName>Brundin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G.</Initials>
                    <FamilyName>Paul</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson’s disease in mice</ArticleTitle>
                  <JournalTitle>Behav. Brain Res.</JournalTitle>
                  <VolumeID>162</VolumeID>
                  <FirstPage>1</FirstPage>
                  <LastPage>10</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15922062</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.bbr.2005.02.023</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXks1ClsLg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Iancu, R., Mohapel, P., Brundin, P., and Paul, G. (2005) Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson’s disease in mice Behav. Brain Res. 162, 1–10.</BibUnstructured>
              </Citation>
              <Citation ID="CR52_10">
                <CitationNumber>52.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Masliah</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Rockenstein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I.</Initials>
                    <FamilyName>Veinbergs</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Mallory</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Hashimoto</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Takeda</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders</ArticleTitle>
                  <JournalTitle>Science</JournalTitle>
                  <VolumeID>287</VolumeID>
                  <FirstPage>1265</FirstPage>
                  <LastPage>1269</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10678833</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1126/science.287.5456.1265</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXhtlOqsL4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., et al (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders Science 287, 1265–1269.</BibUnstructured>
              </Citation>
              <Citation ID="CR53_10">
                <CitationNumber>53.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H.</Initials>
                    <FamilyName>van der Putten</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K.H.</Initials>
                    <FamilyName>Wiederhold</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Probst</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Barbieri</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Mistl</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Danner</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Neuropathology in mice expressing human alpha-synuclein</ArticleTitle>
                  <JournalTitle>J. Neurosci.</JournalTitle>
                  <VolumeID>20</VolumeID>
                  <FirstPage>6021</FirstPage>
                  <LastPage>6029</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10934251</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXlvVGjs74%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>van der Putten, H., Wiederhold, K.H., Probst, A., Barbieri, S., Mistl, C., Danner, S., et al (2000) Neuropathology in mice expressing human alpha-synuclein J. Neurosci. 20, 6021–6029.</BibUnstructured>
              </Citation>
              <Citation ID="CR54_10">
                <CitationNumber>54.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>B.I.</Initials>
                    <FamilyName>Giasson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.E.</Initials>
                    <FamilyName>Duda</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.M.</Initials>
                    <FamilyName>Quinn</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B.</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.Q.</Initials>
                    <FamilyName>Trojanowski</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V.M.</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein</ArticleTitle>
                  <JournalTitle>Neuron</JournalTitle>
                  <VolumeID>34</VolumeID>
                  <FirstPage>521</FirstPage>
                  <LastPage>533</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12062037</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0896-6273(02)00682-7</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XktFSmu74%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Giasson, B.I., Duda, J.E., Quinn, S.M., Zhang, B., Trojanowski, J.Q., and Lee, V.M. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein Neuron 34, 521–533.</BibUnstructured>
              </Citation>
              <Citation ID="CR55_10">
                <CitationNumber>55.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.K.</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W.</Initials>
                    <FamilyName>Stirling</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y.</Initials>
                    <FamilyName>Xu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X.</Initials>
                    <FamilyName>Xu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D.</Initials>
                    <FamilyName>Qui</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.S.</Initials>
                    <FamilyName>Mandir</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Human alpha-synuclein-harboring familial Parkinson’s disease-linked Ala-53 Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice</ArticleTitle>
                  <JournalTitle>Proc. Natl Acad. Sci. USA</JournalTitle>
                  <VolumeID>99</VolumeID>
                  <FirstPage>8968</FirstPage>
                  <LastPage>8973</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12084935</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.132197599</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XltF2htbk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lee, M.K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A.S., et al (2002) Human alpha-synuclein-harboring familial Parkinson’s disease-linked Ala-53 Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice Proc. Natl Acad. Sci. USA 99, 8968–8973.</BibUnstructured>
              </Citation>
              <Citation ID="CR56_10">
                <CitationNumber>56.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P.O.</Initials>
                    <FamilyName>Fernagut</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.F.</Initials>
                    <FamilyName>Chesselet</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Alpha-synuclein and transgenic mouse models</ArticleTitle>
                  <JournalTitle>Neurobiol. Dis.</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <FirstPage>123</FirstPage>
                  <LastPage>130</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15474350</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.nbd.2004.07.001</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXotlSlsLk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Fernagut, P.O. and Chesselet, M.F. (2004) Alpha-synuclein and transgenic mouse models Neurobiol. Dis. 17, 123–130.</BibUnstructured>
              </Citation>
              <Citation ID="CR57_10">
                <CitationNumber>57.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T.D.</Initials>
                    <FamilyName>Stein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.A.</Initials>
                    <FamilyName>Johnson</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways</ArticleTitle>
                  <JournalTitle>J. Neurosci.</JournalTitle>
                  <VolumeID>22</VolumeID>
                  <FirstPage>7380</FirstPage>
                  <LastPage>7388</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12196559</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XmvFCmsLs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Stein, T.D. and Johnson, J.A. (2002) Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways J. Neurosci. 22, 7380–7388.</BibUnstructured>
              </Citation>
              <Citation ID="CR58_10">
                <CitationNumber>58.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J.C.</Initials>
                    <FamilyName>Rochet</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K.A.</Initials>
                    <FamilyName>Conway</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.T.</Initials>
                    <FamilyName>Lansbury</FamilyName>
                    <Suffix>Jr</Suffix>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein</ArticleTitle>
                  <JournalTitle>Biochemistry</JournalTitle>
                  <VolumeID>39</VolumeID>
                  <FirstPage>10619</FirstPage>
                  <LastPage>10626</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10978144</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/bi001315u</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXlsVKlur4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rochet, J.C., Conway, K.A., and Lansbury, P.T., Jr. (2000) Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein Biochemistry 39, 10619–10626.</BibUnstructured>
              </Citation>
              <Citation ID="CR59_10">
                <CitationNumber>59.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.D.</Initials>
                    <FamilyName>Dobrossy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.B.</Initials>
                    <FamilyName>Dunnett</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Optimising plasticity: environmental and training associated factors in transplant-mediated brain repair</ArticleTitle>
                  <JournalTitle>Rev. Neurosci.</JournalTitle>
                  <VolumeID>16</VolumeID>
                  <FirstPage>1</FirstPage>
                  <LastPage>21</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15810651</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Dobrossy, M.D. and Dunnett, S.B. (2005) Optimising plasticity: environmental and training associated factors in transplant-mediated brain repair Rev. Neurosci. 16, 1–21.</BibUnstructured>
              </Citation>
              <Citation ID="CR60_10">
                <CitationNumber>60.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Watts</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.A.</Initials>
                    <FamilyName>Caldwell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.B.</Initials>
                    <FamilyName>Dunnett</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">The development of intracerebral cell-suspension implants is influenced by the grafting medium</ArticleTitle>
                  <JournalTitle>Cell Transplant.</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>573</FirstPage>
                  <LastPage>583</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9853586</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0963-6897(98)00034-7</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK1M%2FmvVCktw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Watts, C., Caldwell, M.A., and Dunnett, S.B. (1998) The development of intracerebral cell-suspension implants is influenced by the grafting medium Cell Transplant. 7, 573–583.</BibUnstructured>
              </Citation>
              <Citation ID="CR61_10">
                <CitationNumber>61.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>V.</Initials>
                    <FamilyName>Johann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Schiefer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Sass</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Mey</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G.</Initials>
                    <FamilyName>Brook</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Kruttgen</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Time of transplantation and cell preparation determine neural stem cell survival in a mouse model of Huntington’s disease</ArticleTitle>
                  <JournalTitle>Exp. Brain Res.</JournalTitle>
                  <VolumeID>177</VolumeID>
                  <FirstPage>458</FirstPage>
                  <LastPage>470</LastPage>
                  <Occurrence Type="PID">
                    <Handle>17013619</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s00221-006-0689-y</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Johann, V., Schiefer, J., Sass, C., Mey, J., Brook, G., Kruttgen, A., et al (2007) Time of transplantation and cell preparation determine neural stem cell survival in a mouse model of Huntington’s disease Exp. Brain Res. 177, 458–470.</BibUnstructured>
              </Citation>
              <Citation ID="CR62_10">
                <CitationNumber>62.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Watts</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I.R.</Initials>
                    <FamilyName>McNamara</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.B.</Initials>
                    <FamilyName>Dunnett</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Volume and differentiation of striatal grafts in rats: relationship to the number of cells implanted</ArticleTitle>
                  <JournalTitle>Cell Transplant.</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>65</FirstPage>
                  <LastPage>72</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10784068</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3c3ksVKmtg%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Watts, C., McNamara, I.R., and Dunnett, S.B. (2000) Volume and differentiation of striatal grafts in rats: relationship to the number of cells implanted Cell Transplant. 9, 65–72.</BibUnstructured>
              </Citation>
              <Citation ID="CR63_10">
                <CitationNumber>63.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G.W.</Initials>
                    <FamilyName>O’ Keeffe</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.M.</Initials>
                    <FamilyName>Sullivan</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Donor age affects differentiation of rat ventral mesencephalic stem cells</ArticleTitle>
                  <JournalTitle>Neurosci. Lett.</JournalTitle>
                  <VolumeID>375</VolumeID>
                  <FirstPage>101</FirstPage>
                  <LastPage>106</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15670650</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.neulet.2004.10.083</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>O’ Keeffe, G.W. and Sullivan, A.M. (2005) Donor age affects differentiation of rat ventral mesencephalic stem cells Neurosci. Lett. 375, 101–106.</BibUnstructured>
              </Citation>
              <Citation ID="CR64_10">
                <CitationNumber>64.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>E.</Initials>
                    <FamilyName>Scherzinger</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.</Initials>
                    <FamilyName>Lurz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Turmaine</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L.</Initials>
                    <FamilyName>Mangiarini</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B.</Initials>
                    <FamilyName>Hollenbach</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.</Initials>
                    <FamilyName>Hasenbank</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo</ArticleTitle>
                  <JournalTitle>Cell</JournalTitle>
                  <VolumeID>90</VolumeID>
                  <FirstPage>549</FirstPage>
                  <LastPage>558</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9267034</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0092-8674(00)80514-0</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXlsVKrsL4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., et al (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo Cell 90, 549–558.</BibUnstructured>
              </Citation>
              <Citation ID="CR65_10">
                <CitationNumber>65.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A.R.</Initials>
                    <FamilyName>Harvey</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N.A.</Initials>
                    <FamilyName>Symons</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.A.</Initials>
                    <FamilyName>Pollett</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G.J.</Initials>
                    <FamilyName>Brooker</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.F.</Initials>
                    <FamilyName>Bartlett</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Fate of adult neural precursors grafted to adult cortex monitored with a Y-chromosome marker</ArticleTitle>
                  <JournalTitle>Neuroreport</JournalTitle>
                  <VolumeID>8</VolumeID>
                  <FirstPage>3939</FirstPage>
                  <LastPage>3943</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9462470</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1097/00001756-199712220-00018</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK1c7it1ejsA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Harvey, A.R., Symons, N.A., Pollett, M.A., Brooker, G.J., and Bartlett, P.F. (1997) Fate of adult neural precursors grafted to adult cortex monitored with a Y-chromosome marker Neuroreport 8, 3939–3943.</BibUnstructured>
              </Citation>
              <Citation ID="CR66_10">
                <CitationNumber>66.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.W.</Initials>
                    <FamilyName>Miller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.S.</Initials>
                    <FamilyName>Nowakowski</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Use of bromodeoxyuridine-immunohistochemistry to examine the proliferation, migration and time of origin of cells in the central nervous system</ArticleTitle>
                  <JournalTitle>Brain Res.</JournalTitle>
                  <VolumeID>457</VolumeID>
                  <FirstPage>44</FirstPage>
                  <LastPage>52</LastPage>
                  <Occurrence Type="PID">
                    <Handle>3167568</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0006-8993(88)90055-8</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaL1M%2Fgt1SrtA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Miller, M.W. and Nowakowski, R.S. (1988) Use of bromodeoxyuridine-immunohistochemistry to examine the proliferation, migration and time of origin of cells in the central nervous system Brain Res. 457, 44–52.</BibUnstructured>
              </Citation>
              <Citation ID="CR67_10">
                <CitationNumber>67.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M.A.</Initials>
                    <FamilyName>Caldwell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X.</Initials>
                    <FamilyName>He</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.N.</Initials>
                    <FamilyName>Svendsen</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">5-Bromo-2’-deoxyuridine is selectively toxic to neuronal precursors in vitro</ArticleTitle>
                  <JournalTitle>Eur. J. Neurosci.</JournalTitle>
                  <VolumeID>22</VolumeID>
                  <FirstPage>2965</FirstPage>
                  <LastPage>2970</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16324131</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1460-9568.2005.04504.x</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Caldwell, M.A., He, X., and Svendsen, C.N. (2005) 5-Bromo-2’-deoxyuridine is selectively toxic to neuronal precursors in vitro Eur. J. Neurosci. 22, 2965–2970.</BibUnstructured>
              </Citation>
              <Citation ID="CR68_10">
                <CitationNumber>68.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>B.R.</Initials>
                    <FamilyName>Christie</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H.A.</Initials>
                    <FamilyName>Cameron</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Neurogenesis in the adult hippocampus</ArticleTitle>
                  <JournalTitle>Hippocampus</JournalTitle>
                  <VolumeID>16</VolumeID>
                  <FirstPage>199</FirstPage>
                  <LastPage>207</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16411231</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/hipo.20151</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XjtV2ktbs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Christie, B.R. and Cameron, H.A. (2006) Neurogenesis in the adult hippocampus Hippocampus 16, 199–207.</BibUnstructured>
              </Citation>
              <Citation ID="CR69_10">
                <CitationNumber>69.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N.D.</Initials>
                    <FamilyName>Bull</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P.F.</Initials>
                    <FamilyName>Bartlett</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">The adult mouse hippocampal progenitor is neurogenic but not a stem cell</ArticleTitle>
                  <JournalTitle>J. Neurosci.</JournalTitle>
                  <VolumeID>25</VolumeID>
                  <FirstPage>10815</FirstPage>
                  <LastPage>10821</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16306394</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1523/JNEUROSCI.3249-05.2005</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXht1yks77O</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bull, N.D. and Bartlett, P.F. (2005) The adult mouse hippocampal progenitor is neurogenic but not a stem cell J. Neurosci. 25, 10815–10821.</BibUnstructured>
              </Citation>
              <Citation ID="CR70_10">
                <CitationNumber>70.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T.C.</Initials>
                    <FamilyName>Burns</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X.R.</Initials>
                    <FamilyName>Ortiz-Gonzalez</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Gutierrez-Perez</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C.D.</Initials>
                    <FamilyName>Keene</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.</Initials>
                    <FamilyName>Sharda</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Z.L.</Initials>
                    <FamilyName>Demorest</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Thymidine analogs are transferred from prelabeled donor to host cells in the central nervous system after transplantation: a word of caution</ArticleTitle>
                  <JournalTitle>Stem Cells</JournalTitle>
                  <VolumeID>24</VolumeID>
                  <FirstPage>1121</FirstPage>
                  <LastPage>1127</LastPage>
                  <Occurrence Type="PID">
                    <Handle>16373692</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1634/stemcells.2005-0463</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XhtFKiu7nI</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Burns, T.C., Ortiz-Gonzalez, X.R., Gutierrez-Perez, M., Keene, C.D., Sharda, R., Demorest, Z.L., et al (2006) Thymidine analogs are transferred from prelabeled donor to host cells in the central nervous system after transplantation: a word of caution Stem Cells 24, 1121–1127.</BibUnstructured>
              </Citation>
              <Citation ID="CR71_10">
                <CitationNumber>71.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>W.T.</Initials>
                    <FamilyName>Hendriks</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.J.</Initials>
                    <FamilyName>Ruitenberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B.</Initials>
                    <FamilyName>Blits</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G.J.</Initials>
                    <FamilyName>Boer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Verhaagen</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Viral vector-mediated gene transfer of neurotrophins to promote regeneration of the injured spinal cord</ArticleTitle>
                  <JournalTitle>Prog. Brain Res.</JournalTitle>
                  <VolumeID>146</VolumeID>
                  <FirstPage>451</FirstPage>
                  <LastPage>476</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14699980</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0079-6123(03)46029-9</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXkslWlsw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hendriks, W.T., Ruitenberg, M.J., Blits, B., Boer, G.J., and Verhaagen, J. (2004) Viral vector-mediated gene transfer of neurotrophins to promote regeneration of the injured spinal cord Prog. Brain Res. 146, 451–476.</BibUnstructured>
              </Citation>
              <Citation ID="CR72_10">
                <CitationNumber>72.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A.</Initials>
                    <FamilyName>Follenzi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L.</Initials>
                    <FamilyName>Naldini</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">HIV-based vectors. Preparation and use</ArticleTitle>
                  <JournalTitle>Methods Mol. Med.</JournalTitle>
                  <VolumeID>69</VolumeID>
                  <FirstPage>259</FirstPage>
                  <LastPage>274</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11987783</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXoslSqsLc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Follenzi, A. and Naldini, L. (2002) HIV-based vectors. Preparation and use Methods Mol. Med. 69, 259–274.</BibUnstructured>
              </Citation>
              <Citation ID="CR73_10">
                <CitationNumber>73.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P.F.</Initials>
                    <FamilyName>Lewis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.</Initials>
                    <FamilyName>Emerman</FamilyName>
                  </BibAuthorName>
                  <Year>1994</Year>
                  <ArticleTitle Language="En">Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus</ArticleTitle>
                  <JournalTitle>J. Virol.</JournalTitle>
                  <VolumeID>68</VolumeID>
                  <FirstPage>510</FirstPage>
                  <LastPage>516</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8254763</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2cXhtVelurw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lewis, P.F. and Emerman, M. (1994) Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus J. Virol. 68, 510–516.</BibUnstructured>
              </Citation>
              <Citation ID="CR74_10">
                <CitationNumber>74.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Y.</Initials>
                    <FamilyName>Liu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B.T.</Initials>
                    <FamilyName>Himes</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Solowska</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J.</Initials>
                    <FamilyName>Moul</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.Y.</Initials>
                    <FamilyName>Chow</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K.I.</Initials>
                    <FamilyName>Park</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Intraspinal delivery of neurotrophin-3 using neural stem cells genetically modified by recombinant retrovirus</ArticleTitle>
                  <JournalTitle>Exp. Neurol.</JournalTitle>
                  <VolumeID>158</VolumeID>
                  <FirstPage>9</FirstPage>
                  <LastPage>26</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10448414</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1006/exnr.1999.7079</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXltVKlsr8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Liu, Y., Himes, B.T., Solowska, J., Moul, J., Chow, S.Y., Park, K.I., et al (1999) Intraspinal delivery of neurotrophin-3 using neural stem cells genetically modified by recombinant retrovirus Exp. Neurol. 158, 9–26.</BibUnstructured>
              </Citation>
              <Citation ID="CR75_10">
                <CitationNumber>75.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T.L.</Initials>
                    <FamilyName>Limke</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.S.</Initials>
                    <FamilyName>Rao</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Neural stem cells in aging and disease</ArticleTitle>
                  <JournalTitle>J. Cell Mol. Med.</JournalTitle>
                  <VolumeID>6</VolumeID>
                  <FirstPage>475</FirstPage>
                  <LastPage>496</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12611637</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1582-4934.2002.tb00451.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3s%2FpvFyqtA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Limke, T.L. and Rao, M.S. (2002) Neural stem cells in aging and disease J. Cell Mol. Med. 6, 475–496.</BibUnstructured>
              </Citation>
              <Citation ID="CR76_10">
                <CitationNumber>76.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C.</Initials>
                    <FamilyName>Watts</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.B.</Initials>
                    <FamilyName>Dunnett</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Effects of severity of host striatal damage on the morphological development of intrastriatal transplants in a rodent model of Huntington’s disease: implications for timing of surgical intervention</ArticleTitle>
                  <JournalTitle>J. Neurosurg.</JournalTitle>
                  <VolumeID>89</VolumeID>
                  <FirstPage>267</FirstPage>
                  <LastPage>274</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9688122</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.3171/jns.1998.89.2.0267</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK1czltFCjug%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Watts, C. and Dunnett, S.B. (1998) Effects of severity of host striatal damage on the morphological development of intrastriatal transplants in a rodent model of Huntington’s disease: implications for timing of surgical intervention J. Neurosurg. 89, 267–274.</BibUnstructured>
              </Citation>
              <Citation ID="CR77_10">
                <CitationNumber>77.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C.N.</Initials>
                    <FamilyName>Svendsen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M.G.</Initials>
                    <FamilyName>ter Borg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R.J.</Initials>
                    <FamilyName>Armstrong</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A.E.</Initials>
                    <FamilyName>Rosser</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S.</Initials>
                    <FamilyName>Chandran</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T.</Initials>
                    <FamilyName>Ostenfeld</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">A new method for the rapid and long term growth of human neural precursor cells</ArticleTitle>
                  <JournalTitle>J. Neurosci. Methods</JournalTitle>
                  <VolumeID>85</VolumeID>
                  <FirstPage>141</FirstPage>
                  <LastPage>152</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9874150</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0165-0270(98)00126-5</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXnsFaju7k%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Svendsen, C.N., ter Borg, M.G., Armstrong, R.J., Rosser, A.E., Chandran, S., Ostenfeld, T., et al (1998) A new method for the rapid and long term growth of human neural precursor cells J. Neurosci. Methods 85, 141–152.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ChapterBackmatter>
        </Chapter>
      </Part>
    </Book>
  </Series>
</Publisher>